Activity levels for diffusing alpha-emitter radiation therapy
Patent Information
- Application Number
- HK42026125083
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-06-10
- Filing Date
- 2026-06-22
- Publication Date
- 2026-09-11
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202610041754.4 (22) Application Date 2022.06.08 (30) Priority Data 17 / 343,786 2021.06.10 US (62) Divisional Application Data 202280005646.1 2022.06.08 (71) Applicant AlphaTao Medical Co., Ltd. Address Jerusalem, Israel (72) Inventors Itzhak Kelsenjona Kesaliamunon Gette Robert Denof Magneto Domankovic Lior Araztomar Kuks Guy Hegelmirta Dumancic Ishai Luzmaya Hedwa Vatarescu (74) Patent Agency Beijing Anxin Fangda Intellectual Property Agency Co., Ltd. 11262 Patent Attorneys: Li Wei, Yang Mingzhao (51) Int.Cl. A61N 5 / 10 (2006.01) (54) Invention Title: Activity Level of Diffused Alpha-Emitter Radiotherapy (57) Abstract: This application relates to the activity level of diffuse alpha-emitter radiotherapy. A method for treating cancerous tumors is disclosed herein, by implanting at least one diffuse alpha-emitter radiotherapy (DaRT) source having a suitable radon release rate and sustained for a given duration into the cancerous tumor, such that the source provides a cumulative radon release activity of at least 10 megabecquerels (MBq) hours per centimeter length during the given duration. Optionally, the source is implanted in the form of an array of sources, wherein each source in the array is spaced no more than 4.5 mm from its neighboring sources. Claims (2 pages), Description (28 pages), Drawings (24 pages), CN 121623181 A, 2026.03.10, CN 1 21 62 31 81 A. 1. A kit for implantation of a diffuse alpha-emitter radiotherapy source in a cancerous tumor, wherein the kit comprises a diffuse alpha-emitter radiotherapy source having radium-224 mounted on a support, wherein the diffuse alpha-emitter radiotherapy sources are implanted in an array, wherein each diffuse alpha-emitter radiotherapy source in the array is spaced no more than 3.9 mm from its adjacent diffuse alpha-emitter radiotherapy source. 2. The kit of claim 1, wherein the diffuse alpha-emitter radiotherapy sources are implanted in a hexagonal arrangement. 3. The kit of claim 1, wherein each diffuse alpha-emitter radiotherapy source in the array is spaced between 3.1 mm and 3.9 mm from its adjacent diffuse alpha-emitter radiotherapy source. 4. The kit of claim 1, wherein each diffuse alpha emitter radiotherapy source in the array is spaced no more than 3.7 mm from its neighboring diffuse alpha emitter radiotherapy source.5. The kit of claim 1, wherein each diffuse alpha emitter radiotherapy source in the array is spaced no more than 3.5 mm from its neighboring diffuse alpha emitter radiotherapy source. 6. The kit of any one of claims 1-5, wherein each diffuse alpha emitter radiotherapy source in the array is spaced at least 3.3 mm from its neighboring diffuse alpha emitter radiotherapy source. 7. The kit of any one of claims 1-5, wherein the cancerous tumor is a melanoma tumor. 8. The kit of any one of claims 1-5, wherein the cancerous tumor is a prostate cancer tumor. 9. The kit of any one of claims 1-5, wherein the cancerous tumor is a pancreatic cancer tumor. 10. The kit of any one of claims 1-5, wherein the cancerous tumor is a glioblastoma tumor. 11. An apparatus for preparing radiotherapy treatment, comprising: an input interface for receiving information about a tumor; a processor configured to identify the tumor as cancerous and generate an arrangement of diffuse alpha emitter radiotherapy sources for the tumor, wherein the diffuse alpha emitter radiotherapy sources in the arrangement are arranged in a regular pattern with a distance of no more than 3.9 mm between adjacent diffuse alpha emitter radiotherapy sources; and an output interface for displaying the arrangement to a human operator. 12. The apparatus of claim 11, wherein the distance between adjacent diffuse alpha emitter radiotherapy sources does not exceed 3.7 mm. 13. The apparatus of claim 11, wherein the diffuse alpha emitter radiotherapy sources in the arrangement are arranged in a hexagonal pattern. 14. The apparatus of claim 11, wherein the distance between adjacent diffuse alpha emitter radiotherapy sources is between 3.1 mm and 3.9 mm. 15. The apparatus of claim 11, wherein the distance between adjacent diffuse alpha emitter radiotherapy sources does not exceed 3.5 mm. 16. A method of preparing for radiotherapy treatment, comprising: receiving a request for diffuse alpha-emitter radiotherapy sources for a cancerous tumor; determining the number of diffuse alpha-emitter radiotherapy sources required for the cancerous tumor, such that a tumor region is covered by diffuse alpha-emitter radiotherapy sources with a spacing between the diffuse alpha-emitter radiotherapy sources not greater than 3.9 mm; and providing a kit comprising the determined number of diffuse alpha-emitter radiotherapy sources. 17. The method of claim 16, wherein determining the number of diffuse alpha-emitter radiotherapy sources required for the cancerous tumor comprises determining the number such that a tumor region is covered by diffuse alpha-emitter radiotherapy sources with a spacing between the diffuse alpha-emitter radiotherapy sources not greater than 3.5 mm.121623181 A Activity Level of Diffuse Alpha-Emitter Radiotherapy
[0001] This application is a divisional application of application filed on June 8, 2022, with application number 202280005646.1 and entitled "Activity Level of Diffuse Alpha-Emitter Radiotherapy". Field of the Invention
[0002] The present invention relates generally to radiotherapy, and particularly to apparatus and methods for delivering tumor-specific radiation doses in radiotherapy treatment. Background of the Invention
[0003] Ionizing radiation is commonly used to treat certain types of tumors, including malignant cancerous tumors, to destroy their cells. However, ionizing radiation can also damage the patient's healthy cells, and therefore care must be taken to minimize the radiation dose delivered to healthy tissue outside the tumor while maximizing the dose delivered to the tumor.
[0004] Ionizing radiation destroys cells by damaging the DNA of the cells. The bioeffectiveness of different types of radiation in killing cells is determined by the type and severity of DNA damage they cause. Alpha particles are a powerful tool in radiotherapy because they induce clusters of double-strand breaks in DNA that cells cannot repair. Unlike conventional types of radiation, the destructive effects of alpha particles are largely unaffected by low cellular oxygen levels, making them equally effective against hypoxic cells, a primary reason for the failure of conventional photon or electron-based radiotherapy in tumors. Furthermore, the short distance (less than 100 micrometers) of alpha particles within tissue ensures that surrounding healthy tissue is spared if the emitting atoms are confined within the tumor volume. On the other hand, the short distance of alpha radiation has so far limited its application in cancer therapy, as there is no practically feasible method to deploy alpha-emitting atoms at a sufficient concentration throughout the entire tumor volume.
[0005] For example, diffuse alpha-emitter radiation therapy (DaRT) described in Kelson's U.S. Patent 8,834,837 extends the therapeutic range of alpha radiation by using radium-223 or radium-224 atoms, which produce several chains of radioactive decay, with radium-224 having a dominant governing half-life of 3.6 days and radium-223 having a dominant half-life of 11.4 days. In DaRT, radium atoms attach to the source implanted in the tumor (also called "seeds") with a strength sufficient to prevent them from leaving the source in a wasteful manner (removed from the tumor via the bloodstream), but a considerable percentage of their daughter radionuclides (radon-220 in the case of radium-224 and radon-219 in the case of radium-223) leave the source and enter the tumor upon radium decay. These radionuclides...Nuclides and their own radioactive daughter atoms diffuse over radial distances of up to several millimeters around the source before decaying through alpha radiation. Therefore, the extent of destruction in the tumor increases relative to the radionuclide that remains on the source with its daughter atoms.
[0006] For tumor treatment to be effective, the DaRT seeds used in the treatment should release a sufficient number of radon atoms to destroy the tumor with a high probability. If the radiation dose used is insufficient, too many cancer cells will remain in the tumor, and these cells can proliferate and reform into a malignant tumor. On the other hand, the seeds should not release too many radon atoms, as some of their daughter atoms are cleared from the tumor through the bloodstream and may therefore damage distant healthy tissues, including the patient's organs such as bone marrow, kidneys, and / or ovaries.
[0007] The amount of radium atoms on the DaRT source is quantified based on activity (i.e., the rate of radium decay). DaRT source activity is measured in microcuries (µCi, see specification page 1 / 28, CN 121623181 A A Ci) or kilobecquerels (kBq), where 1 µCi = 37 kBq = 37,000 decays per second. When using DaRT, the radiation dose delivered to tumor cells depends not only on the radium activity of the source but also on the probability that radon atoms, the daughter atoms, leave the source and enter the tumor during the alpha decay of radium. This probability is referred to herein as the “desorption probability.” Therefore, instead of expressing it in terms of source activity, one can use the “radon release rate” as a measure of the DaRT-related activity of the source, which is defined herein as the product of the source activity and the probability of radon desorption from the source. Similar to activity, the radon release rate is given in µCi or kBq. Unless otherwise stated, the activity and radon release rate values given herein are those of the source activity and radon release rate at the time of source implantation into the tumor.
[0008] The aforementioned Kelson U.S. Patent 8,834,837 suggests using an activity of “about 10 nanocuries to about 10 microcuries, more preferably about 10 nanocuries to about 1 microcurie.” Summary of the Invention
[0009] Embodiments of the present invention relate to providing a precisely tailored dose of radiation to a tumor in radiotherapy treatment. Embodiments include a radiotherapy source designed to provide a suitable dose of radiation, and a kit comprising a suitable number of sources for a tumor of a specific size. Further embodiments relate to methods for preparing a kit of radiotherapy sources for a specific tumor and methods for treating a tumor.
[0010] Thus, according to embodiments of the present invention, a method for treating a tumor is provided, the method comprising identifying a cancerous tumor; and implanting at least one diffuse alpha emitter radiotherapy (DaRT) source having a suitable radon release rate into the cancerous tumor and sustaining it for a given duration, such that the source provides 5.6 megabecquerels (MBq) per centimeter length per hour and 8The cumulative activity of released radon between MBq hours.
[0011] Optionally, implantation of at least one source is performed without identifying the type of cancerous tumor. Optionally, implantation of at least one radiotherapy source comprises an array of implanted sources, in which each source is spaced no more than 4.5 mm from its neighboring sources. Optionally, implantation of at least one radiotherapy source comprises an array of implanted sources, in which each source is spaced no more than 4 mm from its neighboring sources. Optionally, at least one radiotherapy source has a radon release rate between 1.2 microcuries and 2 microcuries per centimeter of length. Optionally, at least one radiotherapy source has a radon release rate between 1.2 microcuries and 1.7 microcuries per centimeter of length. Optionally, at least one radiotherapy source has a radon release rate between 1.3 microcuries and 1.6 microcuries per centimeter of length. Optionally, the method includes selecting a given duration before implanting at least one DaRT source into the tumor, and removing the source from the tumor after the given duration has elapsed since the source implantation began.
[0012] According to an embodiment of the invention, a method for preparing radiotherapy treatment is also provided, the method comprising identifying a cancerous tumor, receiving an image of the tumor; and providing an arrangement of diffuse alpha-emitter radiotherapy (DaRT) sources for the cancerous tumor, wherein the sources have a radon release rate between 1.2 microcuries and 2 microcuries per centimeter of length.
[0013] Optionally, providing the arrangement comprises providing an arrangement in the tumor with a spacing of 4 millimeters or less between the sources. Optionally, the sources have a radon release rate between 1.3 microcuries and 1.6 microcuries per centimeter of length.
[0014] According to an embodiment of the invention, an apparatus for preparing radiotherapy treatment is also provided, the apparatus comprising an input interface for receiving information about a tumor; a processor configured to generate an arrangement of diffuse alpha-emitter radiotherapy (DaRT) sources for the tumor, wherein the sources in the arrangement have a radon release rate between 0.75 microcuries and 2 microcuries per centimeter of length, preferably between 0.75 microcuries and 1.75 microcuries, and the sources in the arrangement are arranged in a regular pattern with a distance of no more than 5 millimeters between adjacent sources; and an output interface for displaying the arrangement to a human operator.
[0015] According to an embodiment of the invention, a method for preparing radiotherapy treatment is also provided, the method comprising receiving a request for diffuse alpha-emitter radiotherapy (DaRT) sources for a tumor, determining a number of radiotherapy sources required for the tumor; and providing a sterile kit comprising the determined number of radiotherapy sources, wherein the sources have a radon release rate between 1.2 microcuries and 1.7 microcuries per centimeter of length.
[0016] Optionally, determining the required number of radiotherapy sources includes determining such that the tumor region is exposed to the source at a rate not exceeding 4 millimeters.The spacing between the sources is such that the required number of sources are covered. Optionally, the sources have a radon release rate between 1.3 and 1.6 microcuries per centimeter of length.
[0017] According to an embodiment of the invention, a diffuse alpha-emitter radiotherapy (DaRT) source for implantation in a tumor is also provided, wherein the DaRT source has a radon release rate between 1.2 and 1.7 microcuries per centimeter of length. Optionally, the radon release rate is between 1.3 and 1.6 microcuries per centimeter of length.
[0018] According to an embodiment of the invention, a kit for a diffuse alpha-emitter radiotherapy (DaRT) source for implantation in a tumor is also provided, the kit comprising a sterile package; and more than one DaRT source placed in the sterile package, the source having a radon release rate between 1.2 and 2 microcuries per centimeter of length, preferably between 1.2 and 1.7 microcuries per centimeter of length. Optionally, the radon release rate of the source is between 1.3 microcuries and 1.6 microcuries per centimeter length.
[0019] According to an embodiment of the invention, a method for treating a tumor is also provided, the method comprising identifying a cancerous tumor; and implanting an array of diffuse alpha-emitter radiotherapy (DaRT) sources into the identified tumor, the diffuse alpha-emitter radiotherapy (DaRT) sources being regularly arranged with a spacing between every two adjacent sources of 3 mm and 4.5 mm. Optionally, the array of implanted sources comprises implantation in a hexagonal arrangement, in which each source in the array is spaced no more than 4 mm from its neighboring sources.
[0020] According to an embodiment of the invention, a method for treating a tumor is also provided, the method comprising identifying a cancerous tumor; and implanting at least one diffuse alpha-emitter radiotherapy (DaRT) source having a suitable radon release rate into the cancerous tumor and sustaining it for a given duration, such that the source provides a cumulative radon activity of at least 10 megabecquerels (MBq) hours per centimeter length during the given duration.
[0021] Optionally, implanting at least one radiotherapy source comprises an array of implanted sources, wherein each source in the array is spaced no more than 4.5 mm from its neighboring sources. Optionally, implanting at least one radiotherapy source comprises an array of implanted sources, wherein each source in the array is spaced no more than 4 mm from its neighboring sources. Optionally, at least one radiotherapy source has a radon release rate of at least 2.3 microcuries per centimeter of length. Optionally, at least one radiotherapy source has a radon release rate of at least 3 microcuries per centimeter of length. Optionally, the method includes selecting a given duration before implanting at least one DaRT source into a tumor, and removing the source from the tumor after the given duration has elapsed since the source implantation began.
[0022] According to an embodiment of the invention, a method for preparing radiotherapy treatment is also provided, the method comprising identifying a cancerous tumor, receiving an image of the tumor; and providing a diffuse alpha-emitter radiotherapy (DaRT) source for the cancerous tumor.An arrangement is provided in which the sources have a radon release rate of at least 2.3 microcuries per centimeter of length. Optionally, providing the arrangement includes providing an arrangement in which the spacing between the sources in the tumor is 4 millimeters or less. Optionally, the sources have a radon release rate of at least 2.7 microcuries per centimeter of length.
[0023] According to an embodiment of the invention, an apparatus for preparing radiotherapy treatment is also provided, the apparatus including an input interface for receiving information about the tumor; a processor configured to generate an arrangement of diffuse alpha-emitter radiotherapy (DaRT) sources for the tumor, wherein the sources in the arrangement have a radon release rate of at least 2.3 microcuries per centimeter of length, and the sources in the arrangement are arranged in a regular pattern with a distance of no more than 5 millimeters between adjacent sources; and an output interface for displaying the arrangement to a human operator.
[0024] According to an embodiment of the invention, a method for preparing radiotherapy treatment is also provided, the method comprising receiving a request for a diffuse alpha-emitter radiotherapy (DaRT) source for a tumor, determining the required number of radiotherapy sources for the tumor; and providing a sterile kit comprising the determined number of radiotherapy sources, wherein the sources have a radon release rate of at least 2.3 microcuries per centimeter of length.
[0025] Optionally, determining the required number of radiotherapy sources includes determining the number of sources required such that the tumor region is covered by the sources with a spacing between the sources of no more than 4 millimeters. Optionally, the sources have a radon release rate of at least 3.4 microcuries per centimeter of length.
[0026] According to an embodiment of the invention, a diffuse alpha-emitter radiotherapy (DaRT) source for implantation in a tumor is also provided, wherein the DaRT source has a radon release rate of at least 2.3 microcuries per centimeter. Optionally, the radon release rate is at least 2.9 microcuries per centimeter of length.
[0027] According to an embodiment of the invention, a kit for implanting a diffuse alpha-emitter radiotherapy (DaRT) source in a tumor is also provided, the kit comprising a sterile package; and more than one DaRT source placed in the sterile package, the source having a radon release rate of at least 2.3 microcuries per centimeter length. Optionally, the radon release rate of the source is at least 3 microcuries per centimeter length.
[0028] According to an embodiment of the invention, a method for treating a tumor is also provided, the method comprising identifying the tumor as a pancreatic cancer tumor, and implanting at least one diffuse alpha-emitter radiotherapy (DaRT) source having a suitable radon release rate in the tumor identified as a pancreatic cancer tumor and sustaining it for a given duration, such that the source provides a cumulative radon activity of release between 5.6 megabecquerels (MBq) hours and 11.6 MBq hours per centimeter length during the given duration.
[0029] Optionally, implanting at least one radiotherapy source comprises an array of implanted sources, in which each source is adjacent to it.The source spacing does not exceed 4 mm. Optionally, implanting at least one radiotherapy source comprises an array of implanted sources arranged in a hexagonal pattern, wherein each source in the array is spaced no more than 4 mm from its neighboring source. Optionally, at least one radiotherapy source has a radon release rate between 1.2 microcuries and 2.5 microcuries per centimeter of length. Optionally, at least one radiotherapy source has a radon release rate between 1.4 microcuries and 1.9 microcuries per centimeter of length. Optionally, the method includes selecting a given duration before implanting at least one DaRT source into the tumor, and removing the source from the tumor after the given duration has elapsed since the source implantation began.
[0030] According to an embodiment of the invention, a method for preparing radiotherapy treatment is also provided, the method comprising identifying the tumor as a pancreatic cancer tumor, receiving an image of the tumor; and providing an arrangement of diffuse alpha-emitter radiotherapy (DaRT) sources for the pancreatic cancer tumor, wherein the sources have a radon release rate between 1.2 microcuries and 2.5 microcuries per centimeter of length. Optionally, providing the arrangement comprises providing an arrangement in the tumor with a spacing of 4 mm or less between the sources. Optionally, the source has a radon release rate between 1.4 microcuries and 1.9 microcuries per centimeter of length.
[0031] According to an embodiment of the invention, an apparatus for preparing radiotherapy treatment is also provided, the apparatus comprising an input interface for receiving information about a tumor; a processor configured to determine that the tumor is a pancreatic cancer tumor and generate an arrangement of diffuse alpha-emitter radiotherapy (DaRT) sources for the tumor, wherein the sources in the arrangement have a radon release rate between 1.2 microcuries and 2.5 microcuries per centimeter of length, and the sources in the arrangement are arranged in a regular pattern with a distance of no more than 4 millimeters between adjacent sources; and an output interface for displaying the arrangement to a human operator.
[0032] According to an embodiment of the invention, a method for preparing radiotherapy treatment is also provided, the method comprising receiving a request for a diffuse alpha-emitter radiotherapy (DaRT) source for a pancreatic cancer tumor, determining the number of radiotherapy sources required for the pancreatic cancer tumor; and providing a sterile kit comprising the determined number of radiotherapy sources, wherein the sources have a radon release rate between 1.2 microcuries and 2.5 microcuries per centimeter of length.
[0033] Optionally, determining the number of radiotherapy sources required includes determining the number of sources required such that the tumor region is covered by the sources with a spacing between the sources not greater than 4 millimeters. Optionally, the sources have a radon release rate between 1.4 microcuries and 1.9 microcuries per centimeter of length.
[0034] According to an embodiment of the invention, a diffuse alpha-emitter radiotherapy (DaRT) source for implantation in a pancreatic cancer tumor is also provided, wherein the DaRT source has a radon release rate between 1.2 microcuries and 2.5 microcuries per centimeter of length.Selectedly, the radon release rate is between 1.4 microcuries and 1.9 microcuries per centimeter of length.
[0035] According to an embodiment of the invention, a kit for implanting a diffuse alpha-emitter radiotherapy (DaRT) source in a pancreatic cancer tumor is also provided, the kit comprising a sterile package; and more than one DaRT source placed in the sterile package, the source having a radon release rate between 1.2 microcuries and 2.5 microcuries per centimeter of length. Optionally, the radon release rate of the source is between 1.4 microcuries and 1.9 microcuries per centimeter of length.
[0036] According to an embodiment of the invention, a method for treating a tumor is also provided, the method comprising identifying the tumor as a pancreatic cancer tumor; and implanting an array of diffuse alpha-emitter radiotherapy (DaRT) sources in the tumor identified as a pancreatic cancer tumor, the diffuse alpha-emitter radiotherapy (DaRT) sources being regularly arranged with a spacing between 3.1 mm and 3.9 mm between every two adjacent sources. Optionally, the array of implanted sources comprises implantation in a hexagonal arrangement.
[0037] According to embodiments of the invention, a method for treating colorectal cancer tumors is also provided, the method comprising identifying the tumor as a colorectal cancer tumor, and implanting at least one diffuse alpha emitter radiotherapy (DaRT) source having a suitable radon release rate into the tumor identified as a colorectal cancer tumor for a given duration, such that the source provides a cumulative radon activity of 3.7 megabecquerels (MBq) hours and 9.2 MBq hours per centimeter length during the given duration.
[0038] Optionally, implanting at least one radiotherapy source comprises an array of implanted sources, wherein each source in the array is spaced no more than 4 mm from its adjacent source. In some embodiments, implanting at least one radiotherapy source comprises an array of implanted sources arranged in a hexagonal pattern, wherein each source in the array is spaced no more than 4 mm from its adjacent source. Optionally, at least one radiotherapy source has a radon release rate between 0.8 microcuries and 2 microcuries per centimeter length. Optionally, at least one radiotherapy source has a radon release rate between 1 microcurie and 1.6 microcuries per centimeter length. Optionally, the method includes selecting a given duration before implanting at least one DaRT source into the tumor, and removing the source from the tumor after the given duration has elapsed since the source implantation began.
[0039] According to an embodiment of the invention, a method for preparing for radiotherapy is also provided, the method comprising identifying the tumor as a colorectal cancer tumor, receiving an image of the colorectal cancer tumor; and providing an arrangement of diffuse alpha-emitter radiotherapy (DaRT) sources for the colorectal cancer tumor, wherein the sources have a radon release rate between 0.8 microcuries and 2 microcuries per centimeter of length. Optionally, providing the arrangement includes providing an arrangement in the tumor with a spacing of 4 millimeters or less between the sources. Optionally, the sources have a radon release rate between 1 microcurie and 1.6 microcuries per centimeter of length.
[0040] According to an embodiment of the invention, an apparatus for preparing radiotherapy treatment is also provided, the apparatus comprising an input interface for receiving information about a tumor; a processor configured to determine that the tumor is a colorectal cancer tumor and generate an arrangement of diffuse alpha-emitter radiotherapy (DaRT) sources for the tumor, wherein the sources in the arrangement have a radon release rate between 0.8 microcuries and 2 microcuries per centimeter of length, and the sources in the arrangement are arranged in a regular pattern with a distance of no more than 5 millimeters between adjacent sources; and an output interface for displaying the arrangement to a human operator.
[0041] According to an embodiment of the invention, a method for preparing radiotherapy treatment is also provided, the method comprising receiving a request for diffuse alpha-emitter radiotherapy (DaRT) sources for a colorectal cancer tumor, determining the number of radiotherapy sources required for the colorectal cancer tumor, and providing a sterile kit comprising the determined number of radiotherapy sources, wherein the sources have a radon release rate between 0.8 microcuries and 2 microcuries per centimeter of length.
[0042] Optionally, determining the required number of radiotherapy sources includes determining the number of sources required to cover the tumor region with a spacing between sources not exceeding 4 millimeters. Optionally, the sources have a radon release rate between 1 microcurie and 1.6 microcurie per centimeter of length.
[0043] According to an embodiment of the invention, a diffuse alpha-emitter radiotherapy (DaRT) source for implantation in a colorectal cancer tumor is also provided, wherein the DaRT source has a radon release rate between 0.8 microcurie and 2 microcurie per centimeter of length. Optionally, the radon release rate is between 1 microcurie and 1.6 microcurie per centimeter of length.
[0044] According to an embodiment of the invention, a kit for implanting a diffuse alpha-emitter radiotherapy (DaRT) source in a colorectal cancer tumor is also provided, the kit comprising a sterile package; and more than one DaRT source placed in the sterile package, the source having a radon release rate between 0.8 microcuries and 2 microcuries per centimeter of length. Optionally, the radon release rate of the source is between 1 microcurie and 1.6 microcuries per centimeter of length.
[0045] According to an embodiment of the invention, a method for treating a tumor is also provided, the method comprising identifying the tumor as a colorectal cancer tumor, and implanting an array of diffuse alpha-emitter radiotherapy (DaRT) sources in the tumor identified as a colorectal cancer tumor, the diffuse alpha-emitter radiotherapy (DaRT) sources being regularly arranged with a spacing between every two adjacent sources of between 3.6 mm and 4.4 mm. Optionally, the array of implanted sources comprises implantation in a hexagonal arrangement, in which each source in the array is spaced no more than 4 mm from its neighboring source.
[0046] According to an embodiment of the present invention, a method for treating squamous cell carcinoma is also provided, the method comprising placing a tumor...The tumor is identified as a squamous cell carcinoma tumor, and at least one diffuse alpha-emitter radiotherapy (DaRT) source with a suitable radon release rate is implanted into the tumor identified as a squamous cell carcinoma tumor and sustained for a given duration, such that the source provides a cumulative radon activity of 3.7 megabecquerels (MBq) hours and 8.6 MBq hours per centimeter length during the given duration.
[0047] Optionally, implanting at least one radiotherapy source comprises an array of implanted sources, in which each source is spaced no more than 4 mm from its neighboring source. In some embodiments, implanting at least one radiotherapy source comprises an array of implanted sources arranged in a hexagonal pattern, in which each source is spaced no more than 4 mm from its neighboring source. Optionally, at least one radiotherapy source has a radon release rate between 0.8 microcuries and 1.85 microcuries per centimeter length. Optionally, at least one radiotherapy source has a radon release rate between 1 microcurie and 1.6 microcuries per centimeter length. Optionally, the method includes selecting a given duration before implanting at least one DaRT source into the tumor, and removing the source from the tumor after the given duration has elapsed since the source implantation began.
[0048] According to an embodiment of the invention, a method for preparing for radiotherapy is also provided, the method comprising identifying the tumor as a squamous cell carcinoma tumor, receiving an image of the squamous cell carcinoma tumor; and providing an arrangement of diffuse alpha-emitter radiotherapy (DaRT) sources for the squamous cell carcinoma tumor, wherein the sources have a radon release rate between 0.8 microcuries and 1.85 microcuries per centimeter of length. Optionally, providing the arrangement includes providing an arrangement in the tumor with a spacing of 4 millimeters or less between the sources. Optionally, the sources have a radon release rate between 1 microcurie and 1.6 microcuries per centimeter of length.
[0049] According to an embodiment of the invention, an apparatus for preparing radiotherapy treatment is also provided, the apparatus comprising an input interface for receiving information about a tumor; a processor configured to determine that the tumor is a squamous cell carcinoma tumor and generate an arrangement of diffuse alpha-emitter radiotherapy (DaRT) sources for the tumor, wherein the sources in the arrangement have a radon release rate between 0.8 microcuries and 1.85 microcuries per centimeter of length, and the sources in the arrangement are arranged in a regular pattern with a distance of no more than 5 millimeters between adjacent sources; and an output interface for displaying the arrangement to a human operator.
[0050] According to an embodiment of the invention, a method for preparing radiotherapy treatment is also provided, the method comprising receiving a request for diffuse alpha-emitter radiotherapy (DaRT) sources for a squamous cell carcinoma tumor, determining the number of radiotherapy sources required for the squamous cell carcinoma tumor, and providing a sterile kit comprising the determined number of radiotherapy sources, wherein the sources have a radon release rate between 0.8 microcuries and 1.85 microcuries per centimeter of length.
[0051] Optionally, determining the required number of radiotherapy sources includes determining the number of sources required to cover the tumor region with a spacing between the sources not exceeding 4 mm. Optionally, the sources have a radon release rate between 1 microcurie and 1.6 microcurie per centimeter of length.
[0052] According to an embodiment of the invention, a diffuse alpha-emitter radiotherapy (DaRT) source for implantation in a squamous cell carcinoma tumor is also provided, wherein the DaRT source has a radon release rate between 0.8 microcurie and 1.85 microcurie per centimeter of length. Optionally, the radon release rate is between 1 microcurie and 1.6 microcurie per centimeter of length.
[0053] According to an embodiment of the invention, a kit for implantation of a diffuse alpha-emitter radiotherapy (DaRT) source in a squamous cell carcinoma tumor is also provided, the kit comprising a sterile package; and more than one DaRT source placed in the sterile package, the source having a radon release rate between 0.8 microcurie and 1.85 microcurie per centimeter of length. Optionally, the radon release rate of the source is between 1 microcurie and 1.6 microcuries per centimeter of length.
[0054] According to an embodiment of the invention, a method for treating a tumor is also provided, the method comprising identifying the tumor as a squamous cell carcinoma tumor, and implanting an array of diffuse alpha-emitter radiotherapy (DaRT) sources into the tumor identified as a squamous cell carcinoma tumor, the diffuse alpha-emitter radiotherapy (DaRT) sources being regularly arranged with a spacing between every two adjacent sources of 3.8 mm and 5 mm. Optionally, the array of implanted sources comprises implantation in a hexagonal arrangement, wherein each source in the array is spaced no more than 4.4 mm from its neighboring sources.
[0055] According to embodiments of the invention, a method for treating glioblastoma tumors is also provided, the method comprising identifying the tumor as a glioblastoma tumor, and implanting at least one diffuse alpha emitter radiotherapy (DaRT) source having a suitable radon release rate into the tumor identified as a glioblastoma tumor for a given duration, such that the source provides a cumulative radon activity of 6.5 megabecquerels (MBq) hours and 14.3 MBq hours per centimeter length during the given duration.
[0056] Optionally, implanting at least one radiotherapy source comprises an array of implanted sources, wherein each source in the array is spaced no more than 4 mm from its neighboring sources. In some embodiments, implanting at least one radiotherapy source comprises an array of implanted sources arranged in a hexagonal pattern, wherein each source in the array is spaced no more than 4 mm from its neighboring sources. Optionally, at least one radiotherapy source has a radon release rate between 1.4 microcuries and 3.1 microcuries per centimeter length. Optionally, at least one radiotherapy source has a radon release rate between 1.8 microcuries and 2.6 microcuries per centimeter of length. Optionally, the method includes selecting a given duration before implanting at least one DaRT source into the tumor, and after the given duration has elapsed from the start of source implantation.Removing the source from the tumor.
[0057] According to an embodiment of the invention, a method for preparing for radiotherapy is also provided, the method comprising identifying the tumor as a glioblastoma tumor, receiving an image of the glioblastoma tumor; and providing an arrangement of diffuse alpha-emitter radiotherapy (DaRT) sources for the glioblastoma tumor, wherein the sources have a radon release rate between 1.4 microcuries and 3.1 microcuries per centimeter of length. Optionally, providing the arrangement comprises providing an arrangement in the tumor with a spacing of 4 millimeters or less between the sources. Optionally, the sources have a radon release rate between 1.8 microcuries and 2.6 microcuries per centimeter of length.
[0058] According to an embodiment of the invention, an apparatus for preparing radiotherapy treatment is also provided, the apparatus comprising an input interface for receiving information about a tumor; a processor configured to determine that the tumor is a glioblastoma tumor and generate an arrangement of diffuse alpha-emitter radiotherapy (DaRT) sources for the tumor, wherein the sources in the arrangement have a radon release rate between 1.4 microcuries and 3.1 microcuries per centimeter of length, and the sources in the arrangement are arranged in a regular pattern with a distance of no more than 5 millimeters between adjacent sources; and an output interface for displaying the arrangement to a human operator.
[0059] According to an embodiment of the invention, a method for preparing radiotherapy treatment is also provided, the method comprising receiving a request for diffuse alpha-emitter radiotherapy (DaRT) sources for glioblastoma tumors, determining the number of radiotherapy sources required for the glioblastoma tumor, and providing a sterile kit comprising the determined number of radiotherapy sources, wherein the sources have a radon release rate between 1.4 microcuries and 3.1 microcuries per centimeter of length.
[0060] Optionally, determining the required number of radiotherapy sources includes determining the number of sources required to cover the tumor region with a spacing between the sources not greater than 4 mm. Optionally, the sources have a radon release rate between 1.8 microcuries and 2.6 microcuries per centimeter of length.
[0061] According to an embodiment of the invention, a diffuse alpha-emitter radiotherapy (DaRT) source for implantation in a glioblastoma tumor is also provided, wherein the DaRT source has a radon release rate between 1.4 microcuries and 3.1 microcuries per centimeter of length. Optionally, the radon release rate is between 1.8 microcuries and 2.6 microcuries per centimeter of length.
[0062] According to an embodiment of the invention, a kit for implantation of a diffuse alpha-emitter radiotherapy (DaRT) source in a glioblastoma tumor is also provided, the kit comprising a sterile package; and more than one DaRT source placed in the sterile package, the source having a radon release rate between 1.4 microcuries and 3.1 microcuries per centimeter of length. Optionally, the radon release rate of the source is between 1.8 microcuries and 2.6 microcuries per centimeter of length.
[0063] According to embodiments of the invention, a method for treating a tumor is also provided, the method comprising identifying the tumor as a glioblastoma tumor, and implanting an array of diffuse alpha-emitter radiotherapy (DaRT) sources into the tumor identified as a glioblastoma tumor, the diffuse alpha-emitter radiotherapy (DaRT) sources being regularly arranged with a spacing between every two adjacent sources of 3.5 mm and 4.5 mm. Optionally, the array of implanted sources comprises implantation in a hexagonal arrangement, in which each source in the array is spaced no more than 4 mm from its neighboring source.
[0064] According to embodiments of the invention, a method for treating a tumor is also provided, the method comprising identifying the tumor as a breast cancer tumor, and implanting at least one diffuse alpha-emitter radiotherapy (DaRT) source having a suitable radon release rate into the tumor identified as a breast cancer tumor and sustaining it for a given duration, such that the source provides a cumulative radon activity of 3.5 megabecquerels (MBq) hours and 9 MBq hours per centimeter length during the given duration.
[0065] Optionally, the tumor comprises a triple-negative breast cancer tumor. Optionally, implanting at least one radiotherapy source comprises an array of implanted sources, wherein each source in the array is spaced no more than 4.5 mm from its neighboring sources. Optionally, at least one radiotherapy source has a radon release rate between 0.8 microcuries and 1.8 microcuries per centimeter of length. In some embodiments, at least one radiotherapy source has a radon release rate between 1.1 microcuries and 1.65 microcuries per centimeter of length. Optionally, the method includes selecting a given duration before implanting at least one DaRT source into the tumor, and removing the source from the tumor after the given duration has elapsed since the source implantation began.
[0066] According to embodiments of the invention, a method for preparing for radiotherapy treatment is also provided, the method comprising identifying the tumor as a breast cancer tumor, receiving an image of the tumor; and providing an arrangement of diffuse alpha-emitter radiotherapy (DaRT) sources for the breast cancer tumor, wherein the sources have a radon release rate between 0.8 microcuries and 1.8 microcuries per centimeter of length. Optionally, providing the arrangement comprises providing an arrangement in the tumor with a spacing of 4 mm or less between the sources. Optionally, the source has a radon release rate between 1.1 microcuries and 1.65 microcuries per centimeter of length.
[0067] According to an embodiment of the invention, an apparatus for preparing radiotherapy treatment is also provided, the apparatus comprising an input interface for receiving information about a tumor; a processor configured to determine that the tumor is a breast cancer tumor and generate an arrangement of diffuse alpha-emitter radiotherapy (DaRT) sources for the tumor, wherein the sources in the arrangement have a radon release rate between 0.8 microcuries and 1.8 microcuries per centimeter of length, and the sources in the arrangement are arranged in a regular pattern with a distance of no more than 5 millimeters between adjacent sources; and an output interface for displaying the arrangement to a human operator.
[0068] According to embodiments of the invention, a method for preparing radiotherapy treatment is also provided, the method comprising receiving a request for a diffuse alpha-emitter radiotherapy (DaRT) source for breast cancer tumors (page 8 / 28 of CN 121623181 A), determining the number of radiotherapy sources required for the breast cancer tumor, and providing a sterile kit comprising the determined number of radiotherapy sources, wherein the sources have a radon release rate between 0.8 microcuries and 1.8 microcuries per centimeter of length. Optionally, determining the number of radiotherapy sources required includes determining the number of sources required such that the tumor region is covered by the sources with a spacing between the sources not greater than 4 millimeters. Optionally, the sources have a radon release rate between 1.1 microcuries and 1.65 microcuries per centimeter of length.
[0069] According to embodiments of the invention, a diffuse alpha-emitter radiotherapy (DaRT) source for implantation in a breast cancer tumor is also provided, wherein the DaRT source has a radon release rate between 0.8 microcuries and 1.8 microcuries per centimeter of length. Optionally, the radon release rate is between 1.1 microcuries and 1.6 microcuries per centimeter length.
[0070] According to an embodiment of the invention, a kit for implanting a diffuse alpha-emitter radiotherapy (DaRT) source in a breast cancer tumor is also provided, the kit comprising a sterile package; and more than one DaRT source placed in the sterile package, the source having a radon release rate between 0.8 microcuries and 1.8 microcuries per centimeter length. Optionally, the radon release rate of the source is between 1.1 microcuries and 1.6 microcuries per centimeter length.
[0071] According to an embodiment of the invention, a method for treating a tumor is also provided, the method comprising identifying the tumor as a breast cancer tumor, and implanting an array of diffuse alpha-emitter radiotherapy (DaRT) sources in the tumor identified as a breast cancer tumor, the diffuse alpha-emitter radiotherapy (DaRT) sources being regularly arranged with a spacing between every two adjacent sources of 3 mm and 4.5 mm. Optionally, the array of implantable sources comprises implanted sources arranged in a hexagonal pattern, with each source in the array spaced no more than 4 mm from its neighboring sources.
[0072] According to an embodiment of the invention, a method for treating melanoma tumors is also provided, the method comprising identifying the tumor as a melanoma tumor; implanting at least one diffuse alpha emitter radiotherapy (DaRT) source having a suitable radon release rate into the tumor identified as a melanoma tumor and sustaining it for a given duration, such that the source provides a cumulative radon activity of 3.2 megabecquerels (MBq) per centimeter length and 7.5 MBq per centimeter length during the given duration.
[0073] Optionally, implanting at least one radiotherapy source comprises an array of implantable sources, with each source in the array spaced no more than 4 mm from its neighboring sources. In some embodiments, implanting at least one radiotherapy source comprises implanted sources arranged in a hexagonal pattern.An array of sources, wherein each source in the array is spaced no more than 4 mm from its neighboring sources. Optionally, at least one radiotherapy source has a radon release rate between 0.67 microcuries and 1.6 microcuries per centimeter of length. Optionally, at least one radiotherapy source has a radon release rate between 0.8 microcuries and 1.5 microcuries per centimeter of length. Optionally, the method includes selecting a given duration before implanting at least one DaRT source into a tumor, and removing the source from the tumor after the given duration has elapsed since the source implantation began.
[0074] According to an embodiment of the invention, a method for preparing for radiotherapy treatment is also provided, the method comprising identifying the tumor as a melanoma tumor, receiving an image of the melanoma tumor; and providing an arrangement of diffuse alpha-emitter radiotherapy (DaRT) sources for the melanoma tumor, wherein the sources have a radon release rate between 0.67 microcuries and 1.6 microcuries per centimeter of length. Optionally, providing the arrangement includes providing an arrangement in the tumor with a spacing of 4 mm or less between the sources. Optionally, the source has a radon release rate between 0.8 microcuries and 1.5 microcuries per centimeter of length.
[0075] According to an embodiment of the invention, an apparatus for preparing radiotherapy treatment is also provided, the apparatus comprising an input interface for receiving information about a tumor; a processor configured to determine that the tumor is a melanoma tumor and generate an arrangement of diffuse alpha-emitter radiotherapy (DaRT) sources for the tumor, wherein the sources in the arrangement have a radon release rate between 0.67 microcuries and 1.6 microcuries per centimeter of length, and the sources in the arrangement are arranged in a regular pattern with a distance of no more than 5 millimeters between adjacent sources; and an output interface for displaying the arrangement to a human operator.
[0076] According to an embodiment of the invention, a method for preparing radiotherapy treatment is also provided, the method comprising receiving a request for a diffuse alpha-emitter radiotherapy (DaRT) source for melanoma tumors (page 9 / 28 of CN 121623181 A), determining the number of radiotherapy sources required for the melanoma tumor, and providing a sterile kit comprising the determined number of radiotherapy sources, wherein the sources have a radon release rate between 0.67 microcuries and 1.6 microcuries per centimeter of length.
[0077] Optionally, determining the number of radiotherapy sources required includes determining the number of sources required such that the tumor region is covered by the sources at a spacing of no more than 4 millimeters between the sources. Optionally, the sources have a radon release rate between 0.8 microcuries and 1.5 microcuries per centimeter of length.
[0078] According to an embodiment of the invention, a diffuse alpha-emitter radiotherapy (DaRT) source for implantation in a melanoma tumor is also provided, wherein the DaRT source has a radon release rate between 0.67 microcuries and 1.6 microcuries per centimeter of length. Optionally, the radon release rate is between 0.8 microcuries and 1.5 microcuries per centimeter of length.
[0079] According to embodiments of the invention, a kit for implanting a diffuse alpha-emitter radiotherapy (DaRT) source into a melanoma tumor is also provided, the kit comprising a sterile package; and more than one DaRT source placed within the sterile package, the source having a radon release rate between 0.67 microcuries and 1.6 microcuries per centimeter of length. Optionally, the radon release rate of the source is between 0.8 microcuries and 1.5 microcuries per centimeter of length.
[0080] According to embodiments of the invention, a method for treating a tumor is also provided, the method comprising identifying the tumor as a melanoma tumor, and implanting an array of diffuse alpha-emitter radiotherapy (DaRT) sources into the tumor identified as a melanoma tumor, the diffuse alpha-emitter radiotherapy (DaRT) sources being regularly arranged with a spacing between every two adjacent sources of 3 mm and 4 mm. Optionally, the array of implanted sources comprises implantation in a hexagonal arrangement, wherein each source in the array is spaced no more than 3.5 mm from its neighboring sources.
[0081] According to embodiments of the invention, a method for treating prostate cancer tumors is also provided, the method comprising identifying the tumor as a prostate cancer tumor; implanting at least one diffuse alpha emitter radiotherapy (DaRT) source having a suitable radon release rate into the tumor identified as a prostate cancer tumor and sustaining it for a given duration, such that the source provides a cumulative radon activity of 7 megabecquerels (MBq) per centimeter length and 14.7 MBq per centimeter length during the given duration.
[0082] Optionally, implanting at least one radiotherapy source comprises an array of implanted sources, wherein each source in the array is spaced no more than 4 mm from its neighboring sources. In some embodiments, implanting at least one radiotherapy source comprises an array of implanted sources arranged in a hexagonal pattern, wherein each source in the array is spaced no more than 4 mm from its neighboring sources. Optionally, at least one radiotherapy source has a radon release rate between 1.5 microcuries and 3.2 microcuries per centimeter length. Optionally, at least one radiotherapy source has a radon release rate between 2 microcuries and 2.7 microcuries per centimeter length. Optionally, the method includes selecting a given duration before implanting at least one DaRT source into the tumor, and removing the source from the tumor after the given duration has elapsed since the source implantation began.
[0083] According to an embodiment of the invention, a method for preparing for radiotherapy is also provided, the method comprising identifying the tumor as a prostate cancer tumor, receiving an image of the prostate cancer tumor; and providing an arrangement of diffuse alpha-emitter radiotherapy (DaRT) sources for the prostate cancer tumor, wherein the sources have a radon release rate between 1.5 microcuries and 3.2 microcuries per centimeter of length. Optionally, providing the arrangement includes providing an arrangement in which the spacing between the sources in the tumor is 4 millimeters or less. Optionally, the sources have a radon release rate between 2 microcuries and 2.7 microcuries per centimeter of length.
[0084] According to an embodiment of the invention, an apparatus for preparing radiotherapy treatment is also provided, the apparatus comprising an input interface for receiving information about a tumor; a processor configured to determine that the tumor is a prostate cancer tumor and generate an arrangement of diffuse alpha-emitter radiotherapy (DaRT) sources for the tumor, wherein the sources in the arrangement have a radon release rate between 1.5 microcuries and 3.2 microcuries per centimeter of length, and the sources in the arrangement are arranged in a regular pattern with a distance of no more than 5 millimeters between adjacent sources; and an output interface for displaying the arrangement to a human operator.
[0085] According to an embodiment of the invention, a method for preparing radiotherapy treatment is also provided, the method comprising receiving a request for diffuse alpha-emitter radiotherapy (DaRT) sources for a prostate cancer tumor, determining the number of radiotherapy sources required for the prostate cancer tumor, and providing a sterile kit comprising the determined number of radiotherapy sources, wherein the sources have a radon release rate between 1.5 microcuries and 3.2 microcuries per centimeter of length.
[0086] Optionally, determining the required number of radiotherapy sources includes determining the number of sources required to cover the tumor region with a spacing between the sources not greater than 4 mm. Optionally, the sources have a radon release rate between 2 microcuries and 2.7 microcuries per centimeter of length.
[0087] According to an embodiment of the invention, a diffuse alpha-emitter radiotherapy (DaRT) source for implantation in a prostate cancer tumor is also provided, wherein the DaRT source has a radon release rate between 1.5 microcuries and 3.2 microcuries per centimeter of length. Optionally, the radon release rate is between 2 microcuries and 2.7 microcuries per centimeter of length.
[0088] According to an embodiment of the invention, a kit for implantation of a diffuse alpha-emitter radiotherapy (DaRT) source in a prostate cancer tumor is also provided, the kit comprising a sterile package; and more than one DaRT source placed in the sterile package, the source having a radon release rate between 1.5 microcuries and 3.2 microcuries per centimeter of length. Optionally, the radon release rate of the source is between 2 microcuries and 2.7 microcuries per centimeter length.
[0089] According to an embodiment of the invention, a method for treating a tumor is also provided, the method comprising identifying the tumor as a prostate cancer tumor, and implanting an array of diffuse alpha-emitter radiotherapy (DaRT) sources into the tumor identified as a prostate cancer tumor, the diffuse alpha-emitter radiotherapy (DaRT) sources being regularly arranged with a spacing between every two adjacent sources of 3 mm and 4 mm. Optionally, the array of implanted sources comprises implantation in a hexagonal arrangement, wherein each source in the array is spaced no more than 3.5 mm from its neighboring sources.
[0090] According to an embodiment of the invention, a diffuse alpha-emitter radiotherapy (DaRT) source for use in treating a patient's cancerous tumor is also provided.A radiotherapy source (DaRT) comprising: a support having a length of at least 1 mm; and radium-224 atoms coupled to the support such that when the source is implanted into the tumor, no more than 20% of the radium-224 atoms leave the support and enter the tumor within 24 hours without decay, but upon decay, at least 5% of the daughter radionuclides of the radium-224 atoms leave the support; characterized in that the application mode of the source comprises implanting the source into the entire tumor of the cancerous tumor, and the spacing between the sources is between 3 mm and 4.5 mm, and the radiotherapy source has a radon release rate between 1.2 microcuries and 2.0 microcuries per centimeter of length.
[0091] Optionally, the application mode of the source comprises implanting the source into the entire tumor of the cancerous tumor, and the spacing between the sources is between 3.1 mm and 3.9 mm. Optionally, the radiotherapy source has a radon release rate between 1.2 and 1.7 microcuries per centimeter of length. Optionally, the radiotherapy source has a radon release rate between 1.3 and 1.6 microcuries per centimeter of length. Optionally, the application mode of the source includes implanting the source into the entire tumor of the cancerous tumor in a hexagonal arrangement, with each source in the array spaced no more than 4.5 millimeters apart from its neighboring sources. Brief Description of the Drawings
[0092] Figure 1 is a schematic diagram of a system for planning radiotherapy treatment according to an embodiment of the present invention; Figure 2 is a flowchart of the actions performed in preparing for radiotherapy treatment of a tumor according to an embodiment of the present invention; Figure 3 is a schematic diagram of a regular arrangement of sources in a hexagonal pattern according to an embodiment of the present invention; Figure 4 is a schematic diagram of a DaRT source kit according to an embodiment of the present invention; Figure 5 is a schematic diagram of a radiotherapy source according to an embodiment of the present invention; Specification 11 / 28 pages 14 CN 121623181 A Figures 6A-6D are graphs illustrating a wide range of radon release rate values required to ensure a nominal alpha particle dose of at least 10 Gy for different seed spacings, lead-212 leakage probabilities, and radon-220 and lead-212 diffusion distances; Figure 6E is a contour plot showing the values of radon release rates required for various possible radon-220 and lead-212 diffusion distances within the range of interest for a 4 mm spacing, 50% lead-212 leakage, and a radiation dose of 10 Gy according to an embodiment of the present invention; Figure 6F is a contour plot illustrating the minimum radiation dose expected to reach tumor cells by various possible radon-220 and lead-212 diffusion distances according to an embodiment of the present invention, assuming a 50% lead-212 leak, with seeds of 3 microcuries per centimeter length implanted in the tumor at a spacing of 4 millimeters; Figures 7A-7G are graphs illustrating various spacings and a series of safety factors for radon release rates for various cancer indications according to embodiments of the present invention.Figure 8A shows the spatial distribution of photoexcited luminescence (PSL) signals in histological sections of a 4T1 tumor, where the sampled data area is indicated in white (0–4 mm) and the fitted area is indicated by a magenta dashed line (0.5–3 mm); Figure 8B is a radial activity distribution map of the sampled data from Figure 8A, fitted with a theoretical model to extract the effective diffusion distance; Figure 8C shows the spatial distribution of PSL in another histological section from the same tumor, where the seed position is automatically determined by calculating the intensity center-of-gravity; Figure 8D is a radial activity distribution map of the sampled data from Figure 8C, fitted with a theoretical model to extract the effective diffusion distance; Figures 9–14 show the effective diffusion distance obtained for different tumor types as a function of tumor mass; Figure 15 shows four histological sections of a DaRT-treated tumor acquired using a digital autoradiography system for measuring radon-220 diffusion distance; Figure 16A shows a single histological section used to measure the radon-220 diffusion distance; and Figure 16B shows the calculated average count as a function of distance from the seed location and the fitted model used to measure the radon-220 diffusion distance. Detailed Description of Embodiments
[0093] Some aspects of embodiments of the present invention relate to setting the radon release rate of a DaRT source for treating different types of tumors based on the characteristics of the tumor. The applicant has created a model to estimate the dose reaching tumor cells as a function of the diffusion distance of lead-212 in the tumor, the diffusion distance of radon-220 in the tumor, and the probability of lead-212 leakage. The diffusion distance represents the typical distance from the point where the atom is produced in the decay of its parent radionuclide to the point where the atom decays. The diffusion distance determines the spatial distribution of diffusing atoms around the seed; as the radial distance from the seed increases by one diffusion distance, the alpha particle dose decreases to about 1 / 3. For a seed with the radon release rate considered herein, the diameter of the region around the seed receiving a 10 Gy alpha particle dose is approximately 10 times larger than the diffusion distance. The appendix describes a method for measuring the effective diffusion distance and thereby estimating the range of diffusion distance values for radon-220 and lead-212. The leakage probability of lead-212 represents the probability that lead-212 atoms released from the source will leave the tumor via the bloodstream before decaying.
[0094] The diffusion distance of radon-220 and the leakage probability of lead-212 have different values in different types of cancerous tumors. Generally, the shorter the diffusion distance of radon-220, the greater the activity required to achieve similar results. The applicant estimated the diffusion distance of radon-220 in various types of tumors and accordingly determined the radon release rate of the source for treating these types of tumors.
[0095] Figure 1 is a schematic diagram of a system 100 for planning radiotherapy treatment according to an embodiment of the present invention. Treatment Manual 12 / 28 pages 15 CNSystem 100 typically involves implanting more than one source into the tumor to be destroyed. System 100 includes an imaging camera 102 that acquires images of the tumor requiring radiotherapy. Additionally, system 100 includes an input interface 104, such as a keyboard and / or mouse, for receiving input from a human operator, such as a physician. Optionally or additionally, system 100 includes a communication interface 106 for receiving instructions and / or data from a remote computer or human operator. System 100 also includes a processor 108 configured to generate a plan of the placement of radiotherapy sources in the tumor and, accordingly, provide details of the individual components of the radiotherapy sources for treating the tumor via an output interface 110. Output interface 110 may be connected to a display and / or a communication network. Processor 108 optionally includes a general-purpose hardware processor configured to run software to perform its tasks described below. Optionally or additionally, processor 108 includes a dedicated processor, such as a signal processing processor, digital signal processor (DSP), or vector processor, configured with suitable software for performing its tasks described herein. In other embodiments, processor 108 includes a dedicated hardware processor, such as an FPGA or ASIC, configured in hardware to perform its tasks.
[0096] In some embodiments, processor 108 is also configured to estimate the radiation dose expected to reach each point in the tumor, for example as described in PCT application PCT / IB2021 / 050034, filed January 5, 2021, entitled “Treatment Planning for Alpha Particle Radiotherapy,” the disclosure of which is incorporated herein by reference.
[0097] FIG2 is a flowchart of the actions performed in preparing for radiotherapy treatment of a tumor according to an embodiment of the invention. The method of FIG2 generally begins with system 100 receiving input about the tumor (such as an image of the tumor and / or the type of the tumor) (202). The spacing between sources to be inserted into the tumor is selected (204), and the number of sources to be included in the treatment kit for the tumor is determined accordingly (206). Furthermore, the duration of treatment is selected (208). The radon release rate of the sources is also selected (210). In some embodiments, a description of the arrangement of the sources in the tumor is also prepared (212). Subsequently, a kit (214) of sources including the selected number is prepared and packaged in a suitable sterile package. In some embodiments, the method further includes a treatment procedure. In these embodiments, the method includes, for example, according to the prepared arrangement (212), […].The source is implanted into the tumor from the kit (216). In some embodiments, the method includes removing the source (218) after a selected duration (208). In other embodiments, the source is not removed but remains in the patient.
[0098] In some embodiments, the type of tumor is determined based on clinical and / or histopathological observations, such as analysis of a portion of the tumor obtained in a biopsy and / or the amount and / or density of blood vessels in the tumor as determined from images of the tumor. The type of tumor is selected, for example, from a list including squamous cell carcinoma, basal cell carcinoma, glioblastoma, sarcoma, pancreatic cancer, lung cancer, prostate cancer, breast cancer, and colorectal cancer.
[0099] In some embodiments, the sources are arranged in a regular geometric pattern, which achieves a relatively low distance between each point in the tumor and at least one of the sources.
[0100] FIG3 is a schematic diagram of a regular arrangement of 160 sources arranged in a hexagonal pattern according to an embodiment of the invention. In the hexagonal arrangement 160, the surface through which the source enters the tumor to be treated is divided into hexagons 164, and the center 162 of each hexagon is designated for the insertion of the source. The center 162 for inserting the source is located at the vertex of an equilateral triangle, and the distance 166 between every two sources is referred to herein as the arrangement spacing. The hexagons 164 are formed by the bisectors of the lines connecting the centers 162 to their six nearest neighboring centers 162. The minimum dose of radiation from the source is at the centroid of the triangle, which is located at the vertex of the hexagon. Optionally, the spacing between the sources is less than 5 mm, no more than 4.5 mm, no more than 4 mm, no more than 3.5 mm, or even no more than 3 mm. As described below, the spacing between the sources is important in determining the treatment plan for a specific cancer type.
[0101] The spacing between the sources is optionally selected (204) as a trade-off between the need to destroy the tumor without using activity levels that may approach safety limits (as per specification page 13 / 28, 16 CN 121623181 A) (which requires a small spacing) and the simplicity of the implantation procedure (which requires a larger spacing). Generally, the largest spacing is selected that is considered to destroy the tumor with seeds having a not excessively high activity level. Since radon-220 and lead-212 have different diffusion distances in different tumor types, and therefore DaRT sources have different effective ranges in different tumor types, the spacing (204) is selected in response to the type of tumor. Furthermore, different tumor types have different required radiation doses. In some embodiments, the spacing (204) is selected according to the type of tumor to be treated. One type of treatment aims to completely destroy tumor cells. Another type of treatment aims to reduce the tumor mass to a size that is not visible to the naked eye, or to a size that makes the tumor resectable. Complete destruction generally requires a higher source activity level and / or a smaller source spacing.
[0102] Optionally or additionally, when selecting the spacing (204), accessibility of the tumor location within the patient's body is taken into consideration. For example, for tumors in internal organs that require access via catheter or endoscopy, a larger spacing is preferred than that used for similar tumors that are easily accessible. In some embodiments, the spacing between sources is selected while taking into account the time and complexity of source implantation. The smaller the spacing, the more sources are required, and therefore the time for source implantation increases. Therefore, according to some embodiments of the invention, the maximum spacing that still allows for tumor destruction is used.
[0103] FIG4 is a schematic diagram of a kit 700 of a DaRT source 21 according to an embodiment of the invention. Kit 700 includes a sterile package 702 that includes more than one alpha-emitter radiotherapy source 21 for insertion into a tumor.
[0104] Optionally, the source 21 is provided within a vial or other housing 706 that prevents radiation from escaping the housing. In some embodiments, the housing is filled with a viscous liquid, such as glycerol, which prevents radon atoms from escaping the housing 706, as described in PCT application PCT / IB2019 / 051834 entitled “Radiotherapy Seeds and Applicators,” the disclosure of which is incorporated herein by reference. In some embodiments, the kit 700 also includes a seed applicator 708 for inserting the source 21 into the patient, as described in PCT application PCT / IB2019 / 051834. Optionally, the applicator 708 is provided to be pre-loaded with one or more sources 21. According to this option, for cases where more than the pre-loaded number of sources is required, individual sources 21 are supplied in the housing 706. Optionally, instead of providing sources 21 in the housing 706, the kit 700 includes only sources within the applicator 708.
[0105] To cover the entire tumor, the number of sources to be included in the treatment kit 700 for the tumor is determined (206) based on the selected spacing and source arrangement. In some embodiments, an additional 10%–20% of sources are provided in the treatment kit.
[0106] The duration of treatment (e.g., the time the seed remains in the tumor) is optionally selected by the operator based on the desired treatment (e.g., complete destruction, mass reduction). In some embodiments, the duration of treatment is pre-selected based on tumor parameters, such as its location in the patient and the patient's availability of the source for removal (208). Alternatively, the duration of treatment is selected based on the progress of treatment during treatment (208).
[0107] The activity of the sources and their desorption probability are optionally selected in response to the selected spacing, treatment duration, and tumor type (210). In some embodiments, the activity of the sources and their desorption probability are also selected in response to the type of tumor to be treated. For example, if the operator indicates that the goal is complete destruction of tumor cells, a higher proportion of sources are used than if the tumor needs to be removed based on visual monitoring.Or reduce the tumor size to make it resectable, indicating a higher activity and / or desorption probability. Optionally, depending on the type of tumor, the purpose of selecting the activity and source probability is to achieve at least a specific radiation dose at each point throughout the tumor (or to achieve a radiation dose at least a threshold percentage above a point throughout the tumor), as discussed in more detail below.
[0108] It should be noted that while the risk of radiation overdose is low for a single small tumor, when treating large tumors and / or multiple tumors, treatment may include the implantation of hundreds of sources. In such cases, it is important to precisely adjust the activity of the sources to prevent excessive radiation to the patient. It is generally considered undesirable to implant activity levels exceeding a few (e.g., 2–5) millicuries in a patient. However, for safety reasons, a limit of about 1 millicurie is currently used. For large tumors requiring seeds of 170 cm or longer (see page 14 / 28 of CN 121623181 A), this sets a limit of about 6 microcuries for the activity of a 1 cm seed. Regarding the radon release rate, given a desorption rate of 38%–45%, this sets a limit of approximately 2.5 microcuries. This limit is not the same for all tumor types. Some tumor types, such as glioblastoma multiforme (GBM), prostate cancer, breast cancer, and squamous cell carcinoma, are generally expected to be treated by radiation when they are small. Therefore, the number of seeds used and their total length are expected to be less than 170 cm so that a higher radon release rate can be used. Other cancer types, such as pancreatic cancer, are expected to require radiation therapy for large tumors. Other cancer types, such as melanoma and colorectal cancer, are expected to require radiation therapy for several different tumors. These cancer types may require seeds with a total length of 170 cm or even longer.
[0109] It should be noted that the behavior in Figure 2 does not necessarily have to be performed in the order in which they are presented. For example, in cases where the source activity is not selected in response to the treatment duration (210), the source activity (210) may be selected before or in parallel with the selection of the treatment duration (208). As another example, the preparation of the arrangement and the preparation of the kit can be performed simultaneously or in any desired order.
[0110] FIG5 is a schematic diagram of a radiotherapy source 21 according to an embodiment of the invention. The radiotherapy source 21 includes a support 22 configured for insertion into a subject. The radiotherapy source 21 also includes radioactive nuclides 26 of radium-224 on the outer surface 24 of the support 22, as described, for example, in U.S. Patent 8,894,969, which is incorporated herein by reference. It should be noted that, for ease of illustration, the atoms 26 and other components of the radiotherapy source 21 are drawn disproportionately large. The atoms 26 are generally arranged such that the radioactive nuclides 26 do not leave the support, but upon radioactive decay, their sub-radioactive...A radionuclide (symbolically shown as 28) can be coupled to the support 22 in such a way that it leaves the support 22 due to the recoil generated by decay. The percentage of radionuclide 28 that leaves the support due to decay is called the desorption probability. In some embodiments, the coupling of atom 26 to the support 22 is achieved by heat treatment. Optionally or additionally, a coating 33 covers the support 22 and the atom 26 in such a way as to prevent the release of radionuclide atom 26 and / or modulate the release rate of radionuclide 28 during radioactive decay. Radionuclides can pass through the coating 33 and leave the radiotherapy source 21 due to recoil, or the recoil can carry them into the coating 33, where they leave by diffusion. In some embodiments, as shown in FIG. 5, in addition to the coating 33, an inner coating 30 of thickness T1 is placed on the support 22, and radionuclide atom 26 is attached to the inner coating 30. However, it should be noted that not all embodiments include an inner coating 30, but rather the radionuclide atom 26 is attached directly to the support 22.
[0111] In some embodiments, the support 22 includes a seed for complete implantation within the patient's tumor, and the support 22 may have any suitable shape, such as a rod or plate. Alternatively, the support 22 may be partially implanted within the patient and is part of a needle, suture, endoscope tip, laparoscopic tip, or any other suitable probe.
[0112] In some embodiments, the support 22 is cylindrical and has a length of at least 1 mm, at least 2 mm, or even at least 5 mm. Optionally, the seed has a length between 5 and 60 mm. The support 22 optionally has a diameter of 0.7 to 1 mm, although in some cases, sources with larger or smaller diameters are used. In particular, for fine-pitch treatment arrangements, the support 22 optionally has a diameter of less than 0.7 mm, less than 0.5 mm, less than 0.4 mm, or even no greater than 0.3 mm.
[0113] The activity on the support 22 is measured herein in microcuries per centimeter of source length. Since the majority of the radiation dose reaching the tumor is determined primarily by the radionuclide leaving the source, the metric for “radon release rate” is defined herein as the product of the activity at the source and the desorption probability. For example, a source having an activity of 2 microcuries per centimeter of length and a desorption probability of 40% has a radon release rate of 0.8 microcuries per centimeter of length.
[0114] The desorption probability depends on the depth of the radionuclide atoms 26 within the surface of the support 22 and / or the type and thickness of the coating 33. Implanting the radionuclide atoms 26 into the surface of the support 22 is typically achieved by heat treatment of the radiotherapy device 21, and the depth of the atoms 26 can be controlled by adjusting the temperature and / or duration of the heat treatment. In some embodimentsIn this case, the desorption probability is between approximately 38% and 45%. Alternatively, a higher desorption probability may be obtained using any of the methods described, for example, in PCT Publication WO 2018 / 207105 entitled "Polymer Coatings for Brachytherapy Devices," the disclosure of which is incorporated herein by reference. In other embodiments, a lower desorption probability may be used, such as that described in U.S. Provisional Patent Application 63 / 126,070 entitled "Diffusing Alpha-emitters Radiation Therapy with Enhanced Beta Treatment," the disclosure of which is incorporated herein by reference.
[0115] It should be noted that not all alpha radiation reaching the tumor is due to the decay of radon-220, a daughter radionuclide 28, which leaves the support 22. Some radon-220 daughter radionuclide 28 produced by the decay of radionuclide atom 26 remains on the support 22. When the daughter radionuclides 28 decay, their daughter radionuclides, such as polonium-216, may leave the support 22 due to recoil, or lead-212 produced during the decay of polonium-216 may leave the support 22 due to recoil.
[0116] Typically, radionuclide atoms 26 are coupled to the support 22 in a manner that prevents the radionuclide atoms 26 from leaving the support 22 on their own. In other embodiments, radionuclide atoms 26 are coupled to the support 22 in a manner that allows the radionuclide atoms 26 to leave the support without decaying (e.g., by diffusion), for example using any of the methods described in PCT Publication WO 2019 / 193464 entitled “Controlled Release of Radionuclides,” which is incorporated herein by reference. Alternatively, diffusion can be achieved by using a bioabsorbable coating that initially prevents the radionuclide atoms 26 from escaping prematurely but disintegrates and allows diffusion after implantation into a tumor.
[0117] The total amount of radiation released by the source in the tumor (referred to herein as the “cumulative radon activity”) depends on the radon release rate of the source and the time the source remains in the tumor. If the source remains in the tumor for a long period, such as a radium-224 source for more than a month, the cumulative radon activity is approximately 0.693, which is the product of the radon release rate of the source multiplied by the average lifetime of radium-224 (3.63 days or 87.12 hours) divided by ln2. For example, a radium-224 source having a radon release rate of 1 microcurie (μCi) = 37,000 becquerels (Bq) has a cumulative radon activity of approximately 4.651 megabecquerels (MBq) hours. It should be noted that an equivalent cumulative radon activity can be achieved by implanting a source with a higher radon release rate over a shorter period of time.For such a short time period, the cumulative activity is given by the following formula:
[0118] where S(0) is the radon release rate when the source is inserted into the tumor, is the mean lifetime of radium-224, and t is the treatment duration in hours. For example, a two-week treatment provides the following cumulative activity:
[0119] The amount of activity on the source required to achieve tumor destruction varies greatly for different types of tumors and source spacing. Therefore, it is important to identify the activity required for that particular tumor type for each type of tumor. A method for calculating the radiation dose reaching each point in the tumor based on the activity of the implanted source is described in U.S. Patent Application 17 / 141,251, filed January 5, 2021, entitled “Treatment Planning for Alpha Particle Radiotherapy,” the disclosure of which is incorporated herein by reference. Using these calculation methods, the required radon release rate can be calculated as a function of the diffusion distance of lead-212 in the tumor, the diffusion distance of radon-220 in the tumor, the spacing between sources implanted in the tumor, the probability of lead-212 leakage from the tumor, and the radiation dose required to reach each location in the tumor.
[0120] Figures 6A-6D are graphs illustrating a wide range of radon release rate values required to ensure a nominal alpha particle dose of at least 10 Gy for different values of the above parameters. The 10 Gy level is chosen as a reference because the required nominal alpha particle dose depends on the tumor type and can be as high as 20-30 Gy. To obtain the seed activity required for a target dose other than 10 Gy, the seed activity of 10 Gy should be multiplied by the ratio between the target dose and 10 Gy. Figure 6A shows the required radon release rate as the lead-212 diffusion distance varies for three different radon-220 diffusion distance values when the lead leakage probability is 80% and the spacing is 3.5 mm. Figure 6B is a similar plot for a 40% lead leakage probability. Figure 6C shows the same plot for a 4 mm spacing and an 80% lead leakage probability, while Figure 6D shows the required radon release rate for a 4 mm spacing and a 40% lead leakage probability. The reader will understand that the range of possible radon release rate values is very large, and the discussion below provides guidance on a narrow range to be used for a specific tumor type.
[0121] Figure 6E is a contour plot showing the values of the required radon release rate for various possible radon-220 and lead-212 diffusion distances within the range of interest for a 4 mm spacing, 50% lead-212 leakage, and a radiation dose of 10 Gy, according to an embodiment of the invention.
[0122] Figure 6F illustrates an embodiment according to the invention, assuming a 50% lead-212 leak, various possible radon-220 andA contour map of the minimum radiation dose expected to reach tumor cells at the lead-212 diffusion distance, with seed particles of 3 microcuries per centimeter length implanted at 4 millimeter intervals within the tumor.
[0123] As can be observed in Figure 6E, the required radon release rate varies considerably for different diffusion distances. Since different tumor types have different diffusion distances, the required radon release rate also differs for different tumor types.
[0124] To estimate the diffusion distances of lead-212 and radon-220 in different types of tumors, the applicant conducted two categories of experiments on different types and sizes of tumors. In the first experimental category, the applicant implanted the source into tumors generated in mice and dissected the tumors several days later to measure the actual activity reaching various points within the tumor. These measurements conformed to the above equations and correspondingly estimated the effective long-term diffusion distance in the tumor. This effective diffusion distance is the larger of the diffusion distances of radon-220 and lead-212.
[0125] Tumors were removed from mice and frozen so that they could be sectioned shortly after removal. The tumors were then sectioned into pieces approximately 10 micrometers thick. Immediately after sectioning, the tissue sections were fixed with formalin for a short duration (minutes) directly onto a glass slide. After fixation, the slides were placed on a Fuji phosphorescent imaging plate in a sealed container for one hour. The slides were separated from the plate by a thin Mylar foil to avoid radioactive contamination. The plate was then scanned using a phosphorescent autoradiography system (Fuji FLA-9000) to record the spatial distribution of lead-212 within the tissue sections.
[0126] Further details regarding the effective long-term diffusion distance measurement are discussed in Appendix A below.
[0127] The second category of experiments was similar to the first, but instead of waiting several days, the tumors were removed approximately half an hour after source insertion. The radioactivity distribution following such a short duration is thought to be primarily due to the diffusion of radon-220, as the spatial distribution of radon-220 stabilizes very quickly, while the contribution from lead-212 increases from zero to a maximum approximately 1.5–2 days after source insertion and remains sufficiently low 30 minutes after source insertion. Details of the measurements of the radon-220 diffusion distance are discussed in Appendix B below.
[0128] Early measurements of the radon-220 diffusion distance found values between 0.23 mm and 0.31 mm. However, the number of measurements was relatively small. Surprisingly, the most recent results of the measurements described above show no significant difference between long-term and short-term experiments. Therefore, the applicant hypothesizes that the diffusion distance of lead-212 is less than that of radon-220. Thus, the applicant hypothesizes that lead-212 is approximately 0.2 mm. This hypothesis is used because, as can be observed in Figure 6E, the diffusion distance values of radon-220 are...Within this range, the dependence on lead-212 diffusion distance is weak. The measured radon-220 diffusion distances for various cancer types are summarized in Table 1 below.
[0129] As is known in the art, different tumor types require different doses of radiation to destroy their cells. Table 1 includes the bioeffective dose (BED) required for various types of cancer tumors in Gray equivalents (GyE) as specified on pages 17 / 28 of the specification, 20 CN 121623181 A. These dose values apply to photon-based radiation (X-rays or gamma rays). Alpha radiation is considered more lethal to cells, and therefore the alpha radiation dose in Gray is multiplied by a correction factor called the relative biological effect (RBE) (currently estimated at 5) to convert it to a BED in Gray equivalents (GyE). The BED in DaRT is the sum of the alpha dose multiplied by the RBE and the β dose produced by radium-224 and its daughters.
[0130] The probability of lead-212 leakage is relatively low at the tumor center but reaches approximately 80% around the tumor periphery. To ensure complete cell destruction of the entire tumor, the applicant used an 80% leakage probability value when selecting the radon release rate of the source.
[0131] To estimate the required spacing and radon release rate for seeding for a specific tumor type, the applicant estimated the required dose for the tumor type, the β radiation dose provided by a span of activity levels, and the remaining required dose to be provided by α radiation. The α radiation dose was estimated for a span of spacing and radon release rate, and a safety factor (the ratio between the estimated provided dose and the required dose) was calculated for that span of spacing and radon release rate. A safety factor is needed to overcome inaccuracies that may occur in the placement of the sources, such that some sources may be spaced at intervals greater than the specified spacing. In addition, tumors may be heterogeneous, causing some local variations in diffusion distance.
[0132] The applicant selected a safety factor range between 1.5 and 4 as the range for defining the required spacing and radon release range for treatment. This safety factor is considered to provide sufficient safety so that the tumor will be destroyed by the provided radiation without being too high and exposing the patient to the risk of systemic radiation from lead-212 leaking from the tumor through the blood and subsequently being absorbed into various organs.
[0133] For a given tumor type, the same safety factor can be achieved with different spacing and radon release rate pairs. If the sources will be placed with a relatively high spacing between them (such as 4.5 mm or 5 mm), the sources should have a high radon release rate, such as more than 1.5 microcuries per centimeter of length. Conversely, when the spacing between the sources is less than 4 mm, the sources can be configured with a relatively low radon release rate.
[0134] Table 1
[0135] Given the selected safety factor range, an appropriate source spacing is selected. As stated above, the largest spacing is considered to destroy the tumor with seeds having a level of activity that is not excessively high. The applicant has limited the selection of the spacing to 0.5.The step size is mm, which is considered close to the level of inaccuracy in seed placement. These inaccuracies are taken into account in the safety factor.
[0136] After selecting the spacing, a range of radon release rates corresponding to that spacing and the safety factor is selected. This range of radon release rates is considered to provide optimal results for treating tumors of the type of tumor for which calculations were performed. It should be noted that the selected range of radon release rates is not limited to use at a specific spacing used for the selection range, but can be used at a range of spacings around the selected spacing due to the safety margin.
[0137] For pancreatic cancer, as stated in Table 1, the effective long-term diffusion distance for pancreatic cancer is estimated to be about 0.29 mm, and the required dose is about 100 GyE.
[0138] Table 2A presents the β dose, the corresponding required α radiation dose, the estimated α radiation dose, and the resulting safety factor for several spacings and radon release rates for pancreatic cancer. Figure 7A is a graph illustrating various spacings and a series of safety factors for radon release rates for pancreatic cancer according to embodiments of the present invention.
[0139] Table 2A - Pancreatic Cancer
[0140] From Figure 7A, the applicant determined that a spacing of 4 mm would require the grains to have a radon release rate significantly higher than 2.5 microcuries. To avoid such high levels of radioactivity, a spacing of 3.5 mm was assumed when selecting the radon release rate of the source. The actual spacing used was optionally shorter than 3.9 mm, shorter than 3.8 mm, shorter than 3.7 mm, or even shorter than 3.6 mm. On the other hand, the actual spacing used was optionally greater than 3.1 mm, greater than 3.2 mm, greater than 3.3 mm, or even greater than 3.4 mm.
[0141] For a spacing of 3.5 mm, a radon release rate between 1.2 microcuries and 2.5 microcuries per centimeter of length was selected to achieve sufficient destruction of the tumor without exposing the patient to unwanted radiation. For long-term treatment, this corresponds to a cumulative radon activity between approximately 5.6 MBqh per centimeter and 11.6 MBqh per centimeter.
[0142] In some embodiments, to increase the probability of treatment success, radon release rates of at least 1.4 microcuries per centimeter, at least 1.5 microcuries per centimeter, at least 1.7 microcuries per centimeter, or even at least 1.8 microcuries per centimeter are used for pancreatic cancer. On the other hand, in some embodiments, to reduce the amount of radiation exposed to the patient, radon release rates are no greater than 2.2 microcuries per centimeter, no greater than 2.0 microcuries per centimeter, no greater than 1.8 microcuries per centimeter, or even no greater than 1.75 microcuries per centimeter. In other embodiments, a safety factor between 1.5 and 2.5 is used, and therefore the radon release rate is between 1.2 microcuries and 1.85 microcuries per centimeter. In still other embodiments, a safety factor between 3 and 4 is used, andTherefore, the radon release rate of kernel 21 is between 2.1 microcuries and 2.5 microcuries per centimeter of length.
[0143] Optionally or additionally, the source may optionally include at least 5.9 MBqh per centimeter, at least 6.4 MBqh per centimeter, at least 6.8 MBqh per centimeter, or even at least 7.3 MBqh per centimeter. On the other hand, the source may optionally include less than 10.5 MBqh per centimeter or even less than 9 MBqh per centimeter. Specification 19 / 28 pages 22 CN 121623181 A
[0144] In some cases, for example when a spacing of less than 3.5 mm (such as about 3.2 mm) can be achieved with reasonable precision, the radon release rate of the kernel may be in the lower part of the above range, for example less than 1.5 microcuries per centimeter of length or even less than 1.4 microcuries per centimeter of length.
[0145] Based on the measurements presented in Table 1, the effective long-term diffusion distance for breast cancer is estimated to be 0.35 mm, and the required radiation dose is approximately 60 GyE.
[0146] Table 2B presents several spacings and radon release rates for breast cancer, the corresponding required alpha radiation dose, the estimated alpha radiation dose, and the resulting safety factor.
[0147] Figure 7B is a graph illustrating various spacings and a series of safety factors for radon release rates for breast cancer according to embodiments of the present invention.
[0148] Table 2B - Breast Cancer
[0149] From Table 2B, the applicant determined that a spacing of 4 mm is sufficient. The actual spacing used is optionally shorter than 4.4 mm, shorter than 4.3 mm, shorter than 4.2 mm, or even shorter than 4.1 mm. On the other hand, the actual spacing used is optionally greater than 3.6 mm, greater than 3.7 mm, greater than 3.8 mm, or even greater than 3.9 mm.
[0150] For a 4 mm spacing, the required radon release rate for a safety factor between 1.5 and 4 ranges from approximately 0.8 to 1.8 microcuries per centimeter length. For long-term treatment, this corresponds to a cumulative radon activity released between approximately 3.5 MBqh per centimeter and 9 MBqh per centimeter.
[0151] In some embodiments, to increase the probability of treatment success, radon release rates of at least 1 microcurie per centimeter length, at least 1.1 microcurie per centimeter length, at least 1.25 microcurie per centimeter length, or even at least 1.4 microcurie per centimeter length are used for breast cancer. On the other hand, in some embodiments, to reduce the amount of radiation exposed to the patient, radon release rates of no more than 1.65 microcurie per centimeter length, no more than 1.60 microcurie per centimeter length, or even no more than 1.55 microcurie per centimeter length are used. In other embodiments, a safety factor between 1.5 and 2.5 is used, and therefore the radon release rate is 0.8 microcurie per centimeter length.Between 1.55 and 1.35 microcuries. In other embodiments, a safety factor between 3 and 4 is used, and thus the radon release rate of grain 21 is between 1.55 and 1.8 microcuries per centimeter of length.
[0152] Optionally or additionally, the source optionally includes at least 4 MBqh per centimeter, at least 4.5 MBqh per centimeter, at least 5.5 MBqh per centimeter, or even at least 6.5 MBqh per centimeter. On the other hand, the source optionally includes less than 7.5 MBqh per centimeter or even less than 7 MBqh per centimeter.
[0153] As stated in Table 1, the effective long-term diffusion distance for melanoma is estimated to be about 0.4 mm, and the required dose is about 150 GyE, as stated in the instruction manual 20 / 28 pages 23 CN 121623181 A.
[0154] Table 2C presents the β dose, corresponding required α radiation dose, estimated α radiation dose, and obtained safety factor for several spacings and radon release rates used for melanoma.
[0155] Table 2C - Melanoma
[0156] Figure 7C is a graph showing the safety factor for various spacings used for melanoma according to embodiments of the invention, as a function of radon release rate.
[0157] From Figure 7C, the applicant determined that in the upper part of the safety factor range of 1.5-4, a spacing of 4 mm would require a radon release rate significantly higher than 2.5 microcuries for the grains. To avoid such a high level of radioactivity, a spacing of 3.5 mm is assumed when selecting the radon release rate of the source. The actual spacing used is optionally shorter than 3.9 mm, shorter than 3.8 mm, shorter than 3.7 mm, or even shorter than 3.6 mm. On the other hand, the actual spacing used is optionally greater than 3.1 mm, greater than 3.2 mm, greater than 3.3 mm, or even greater than 3.4 mm.
[0158] For a 3.5 mm spacing, a radon release rate between 0.67 and 1.6 microcuries per centimeter length is considered to achieve sufficient tumor destruction with a high probability without unnecessarily exposing the patient to unwanted radiation. For long-term treatment, this corresponds to a cumulative radon activity released between approximately 3.2 MBqh and 7.5 MBqh per centimeter.
[0159] In some embodiments, to increase the probability of treatment success, radon release rates of at least 1.0 microcuries per centimeter length, at least 1.2 microcuries per centimeter length, at least 1.4 microcuries per centimeter length, or even at least 1.5 microcuries per centimeter length are used for melanoma. On the other hand, in some embodiments, to reduce the amount of radiation exposed to the patient, radon release rates of no more than 1.5 microcuries per centimeter length, no more than 1.4 microcuries per centimeter length, or even no more than 1.3 microcuries per centimeter length are used. In other implementations, a safety factor between 1.5 and 2.5 is used, resulting in a radon release rate of 0.67 microcuries per centimeter of length.Between 1.25 and 1.1 microcuries. In other embodiments, a safety factor between 3 and 4 is used, and thus the radon release rate of grain 21 is between 1.25 and 1.6 microcuries per centimeter length.
[0160] Optionally or additionally, the source optionally includes at least 3.5 MBqh per centimeter, at least 4.5 MBqh per centimeter, at least 5.5 MBqh per centimeter, or even at least 6.5 MBqh per centimeter. On the other hand, in some embodiments, the source includes less than 7 MBqh per centimeter or even less than 6.5 MBqh per centimeter.
[0161] As stated in Table 1, the effective long-term diffusion distance for glioblastoma is estimated to be about 0.27 mm, and the required dose is about 100 GyE.
[0162] Table 2D presents the β dose, the corresponding required α radiation dose, the estimated α radiation dose, and the resulting safety factor for several spacings and radon release rates for glioblastoma. Instruction manual, pages 21 / 28, CN 121623181 A
[0163] Figure 7D is a graph showing the safety factor of various spacings for glioblastoma as a function of radon release rate according to embodiments of the present invention.
[0164] Table 2D - Glioblastoma
[0165] From Figure 7D, the applicant determined that a spacing of 4 mm would require the grain to have a radon release rate significantly higher than 2.5 microcuries. To avoid such a high level of radioactivity, a spacing of 3.5 mm is assumed when selecting the radon release rate of the source. The actual spacing used is optionally shorter than 3.9 mm, shorter than 3.8 mm, shorter than 3.7 mm, or even shorter than 3.6 mm. On the other hand, the actual spacing used is optionally greater than 3.1 mm, greater than 3.2 mm, greater than 3.3 mm, or even greater than 3.4 mm.
[0166] For a 3.5 mm spacing, a safety factor between 1.5 and 4 corresponds to a radon release rate between 1.4 and 3.1 microcuries per centimeter of length. While the upper end of this range is relatively high, this range of radon release rates is reasonable given the importance of success in tumors within the patient's head, the difficulty of access, and the fact that the tumor is expected to be relatively small. For long-term treatment, this corresponds to a cumulative radon activity released between approximately 6.5 MBqh and 14.3 MBqh per centimeter.
[0167] In some embodiments, to increase the probability of treatment success, radon release rates of at least 1.5 microcuries per centimeter of length, at least 1.7 microcuries per centimeter of length, at least 1.8 microcuries per centimeter of length, or even at least 2.0 microcuries per centimeter of length are used for glioblastoma. In some implementation schemes, to reduce the amount of radiation exposed to patients, the radon release rate is set at no more than 3.0 microcuries, no more than 2.8 microcuries, no more than 2.5 microcuries, or even no more than [amount missing] per centimeter of length.2.2 microcuries. In other embodiments, a safety factor between 1.5 and 2.5 is used, and therefore the radon release rate is between 1.4 and 2.3 microcuries per centimeter of length. In still other embodiments, a safety factor between 3 and 4 is used, and therefore the radon release rate of the grain 21 is between 2.65 and 3.1 microcuries per centimeter of length.
[0168] Optionally or additionally, the source optionally includes at least 7 MBq hours per centimeter, at least 8 MBq hours per centimeter, at least 9 MBq hours per centimeter, or even at least 10 MBq hours per centimeter. On the other hand, the source optionally includes less than 12 MBq hours per centimeter or even less than 11 MBq hours per centimeter. Specification 22 / 28 pages 25 CN 121623181 A
[0169] As stated in Table 1, the effective long-term diffusion distance for colorectal cancer is estimated to be about 0.44 mm, and the required radiation dose is about 120 GyE.
[0170] Table 2E presents the β dose, corresponding required α radiation dose, estimated α radiation dose, and obtained safety factor for several spacings and radon release rates for colorectal cancer.
[0171] Figure 7E is a graph illustrating various spacings and a series of safety factors for radon release rates for colorectal cancer according to embodiments of the invention.
[0172] From Figure 7E, the applicant determined that a spacing of 4 mm is sufficient. The actual spacing used is optionally shorter than 4.4 mm, shorter than 4.3 mm, shorter than 4.2 mm, or even shorter than 4.1 mm. On the other hand, the actual spacing used is optionally greater than 3.6 mm, greater than 3.7 mm, greater than 3.8 mm, or even greater than 3.9 mm.
[0173] Table 2E - Colorectal Cancer
[0174] For a spacing of 4 mm, the required radon release rate for a safety factor between 1.5 and 4 is between 0.8 microcuries and 2 microcuries per centimeter length. For long-term treatment, this corresponds to a cumulative radon activity between approximately 3.7 MBqh per centimeter and 9.2 MBqh per centimeter.
[0175] In some embodiments, to increase the probability of treatment success, radon release rates of at least 0.9 microcuries per centimeter, at least 1.05 microcuries per centimeter, at least 1.2 microcuries per centimeter, or even at least 1.3 microcuries per centimeter are used for colorectal cancer. On the other hand, in some embodiments, to reduce the amount of radiation exposed to the patient, radon release rates of no more than 1.7 microcuries per centimeter, no more than 1.6 microcuries per centimeter, no more than 1.5 microcuries per centimeter, or even no more than 1.4 microcuries per centimeter are used. In other embodiments, a safety factor between 1.5 and 2.5 is used, and therefore the radon release rate is between 0.8 and 1.3 microcuries per centimeter. In still other embodiments, a safety factor between 3 and 4 is used.The number, and therefore the radon release rate of seed 21 is between 1.55 microcuries and 2 microcuries per centimeter length.
[0176] Optionally or additionally, the source may optionally include at least 3.9 MBqh per centimeter, at least 4.4 MBqh per centimeter, at least 4.9 MBqh per centimeter, or even at least 5.3 MBqh per centimeter. On the other hand, the source may optionally include less than 8 MBqh per centimeter or even less than 7.5 MBqh per centimeter.
[0177] As stated in Table 1, the effective long-term diffusion distance for squamous cell carcinoma is estimated to be about 0.44 mm, and the required radiation dose is about 60 GyE.
[0178] Table 2F presents the β dose, the corresponding required α radiation dose, the estimated α radiation dose, and the resulting safety factor for several spacings and radon release rates for squamous cell carcinoma. Instructions for Use, Pages 23 / 28, CN 121623181 A
[0179] Figure 7F is a graph showing the safety factors for various spacings and a series of radon release rates for squamous cell carcinoma according to embodiments of the invention.
[0180] Table 2F - Squamous Cell Carcinoma
[0181] From Figure 7F, the applicant determined that a spacing of 4.5 mm is sufficient. The actual spacing used is optionally shorter than 4.9 mm, shorter than 4.8 mm, shorter than 4.7 mm, or even shorter than 4.6 mm. On the other hand, the actual spacing used is optionally greater than 3.6 mm, greater than 3.7 mm, greater than 3.8 mm, or even greater than 3.9 mm.
[0182] For a spacing of 4.5 mm, the radon release rate required for a safety factor between 1.5 and 4 ranges from 0.8 microcuries per centimeter length to 1.85 microcuries per centimeter length. For long-term treatment, this corresponds to a cumulative radon activity released between approximately 3.7 MBqh per centimeter and 8.6 MBqh per centimeter.
[0183] In some embodiments, to increase the probability of treatment success, radon release rates of at least 0.9 microcuries per centimeter length, at least 1 microcurie per centimeter length, at least 1.2 microcuries per centimeter length, or even at least 1.3 microcuries per centimeter length are used for squamous cell carcinoma. On the other hand, in some embodiments, to reduce the amount of radiation exposed to the patient, radon release rates of no more than 1.6 microcuries per centimeter length, no more than 1.5 microcuries per centimeter length, no more than 1.4 microcuries per centimeter length, or even no more than 1.3 microcuries per centimeter length are used. In other embodiments, a safety factor between 1.5 and 2.5 is used, and therefore the radon release rate of the seed 21 is between 0.8 microcuries per centimeter length and 1.27 microcuries per centimeter length. In still other embodiments, a safety factor between 3 and 4 is used, and therefore the radon release rate of the seed 21 is between 1.5 microcuries per centimeter length and 1.85 microcuries per centimeter length.
[0184] Optionally or additionally, the source may optionally include at least 3.8 MBq / hour and at least 4.4 MBq / hour per centimeter.MBq hours, at least 4.9 MBq hours per centimeter, or even at least 5.5 MBq hours per centimeter. On the other hand, sources optionally include less than 7.6 MBq hours per centimeter or even less than 7 MBq hours per centimeter.
[0185] For prostate cancer, as stated in Table 1, the effective long-term diffusion distance for prostate cancer is estimated to be about 0.32 mm, and the required dose is about 173 GyE.
[0186] Table 2G presents several spacings and radon release rates for prostate cancer, the corresponding required alpha radiation dose, the estimated alpha radiation dose, and the resulting safety factor.
[0187] Figure 7G is a graph showing the safety factor for various spacings for prostate cancer according to embodiments of the invention as a function of radon release rate.
[0188] From Figure 7G, the applicant determined that a spacing of 4 mm would require the grains to have a radon release rate significantly higher than 2.5 microcuries. To avoid such a high level of radioactivity, a spacing of 3.5 mm is assumed when selecting the radon release rate of the source. The actual spacing used is optionally shorter than 3.9 mm, shorter than 3.8 mm, shorter than 3.7 mm, or even shorter than 3.6 mm. On page 24 / 28 of the other specification, CN 121623181 A, the actual spacing used is optionally greater than 3.1 mm, greater than 3.2 mm, greater than 3.3 mm, or even greater than 3.4 mm.
[0189] Table 2G – Prostate Cancer
[0190] For a spacing of 3.5 mm, a safety factor between 1.5 and 4 corresponds to a radon release rate between 1.5 and 3.2 microcuries per centimeter of length. While the upper part of this range is relatively high, this range of radon release rates is reasonable given the relatively small expected size of prostate cancer tumors. For long-term treatment, this corresponds to a cumulative radon activity released between approximately 7 MBqh per centimeter and 14.7 MBqh per centimeter.
[0191] In some embodiments, to increase the probability of treatment success, a radon release rate of at least 1.6 microcuries per centimeter length, at least 1.7 microcuries per centimeter length, at least 1.8 microcuries per centimeter length, or even at least 2.0 microcuries per centimeter length is used for prostate cancer. In some embodiments, to reduce the amount of radiation exposed to the patient, a radon release rate of no more than 3.0 microcuries per centimeter length, no more than 2.8 microcuries per centimeter length, no more than 2.5 microcuries per centimeter length, or even no more than 2.2 microcuries per centimeter length is used. In other embodiments, a safety factor between 1.5 and 2.5 is used, and therefore the radon release rate is between 1.5 and 2.3 microcuries per centimeter length. In still other embodiments, a safety factor between 3 and 4 is used, and therefore the radon release rate of the seed 21 is between 2.7 and 3.2 microcuries per centimeter length.
[0192] Optionally or additionally, the source optionally includes at least 8 microcuries per centimeter length.MBq hours, at least 8.8 MBq hours per centimeter, at least 9.6 MBq hours per centimeter, or even at least 10.4 MBq hours per centimeter. Alternatively, sources may include less than 12 MBq hours per centimeter or even less than 11 MBq hours per centimeter.
[0193] Other considerations: In some embodiments, the exact radon release rate within the range is selected in response to the duration of treatment. If a long duration of at least about 10 days or even at least 14 days is used, a lower radon release rate is used. In contrast, for short treatment durations, such as less than 100 hours or even less than 50 hours, the source is configured for a higher radon release rate.
[0194] In some embodiments, a radon release rate between 1.2 microcuries and 1.7 microcuries per centimeter of length is used. Instructions for Use, pages 25 / 28, CN 121623181 A. More specifically, optionally, a radon release rate between 1.3 and 1.6 microcuries per centimeter of length or between 1.4 and 1.5 microcuries per centimeter of length is used. For long-term treatment, this is approximately equivalent to a cumulative activity of released radon between about 5.6 MBqh and 8 MBqh per centimeter.
[0195] Alternatively, slightly higher levels of radon release rates can be used to focus more on combating cancer types with shorter effective diffusion distances. According to these alternatives, a radon release rate between about 1.2 and 2 microcuries per centimeter of length is used, or more specifically, between 1.5 and 1.9 microcuries per centimeter of length or even between 1.6 and 1.8 microcuries per centimeter of length.
[0196] In the above description of high-radiotherapy, the risk of damage to distant healthy tissue from implanted radiation is addressed by selecting the activity of the source. However, in other embodiments, the danger from implanted radiation is addressed in other ways, or is ignored due to a greater danger, and therefore some or all of the sources used have much higher activities than discussed above. For example, high-activity sources can be used in cases of highly aggressive tumors, and / or patients with a single small tumor.
[0197] Higher-activity sources optionally have radon release rates of at least 2.3 microcuries per centimeter length, at least 3 microcuries per centimeter length, at least 3.5 microcuries per centimeter length, at least 4 microcuries per centimeter length, or even at least 5 microcuries per centimeter length. Optionally or additionally, the source has a cumulative radon release activity of at least 10 MBqh per centimeter, at least 10.5 MBqh per centimeter, at least 12 MBqh per centimeter, or even at least 14 MBqh per centimeter.
[0198] It should be noted that in some embodiments, sources with even higher activities are used, for example when it is difficult to ensure that the source is inserted at a prescribed spacing, for example due to difficulty in accessing the tumor, and / or when the spacing is planned to be relatively large. Optionally, in thisIn some embodiments, the sources have a radon release rate of at least 4.5 microcuries per centimeter of length, at least 5 microcuries per centimeter of length, at least 5.5 microcuries per centimeter of length, or even at least 6 microcuries per centimeter of length.
[0199] While in some embodiments all sources implanted in a single tumor have the same radon release rate, in other embodiments, sources implanted in a single tumor have more than one different radon release rate. These embodiments can be used when some parts of the tumor are more accessible than others, and / or when some parts of the tumor allow for shorter spacing between sources than others. Optionally or additionally, sources implanted around the tumor have a higher radon release rate than sources in the center of the tumor. Optionally, the sources are color-coded or otherwise clearly marked to prevent physician confusion when implanting the sources.
[0200] Conclusion It should be understood that the above methods and devices are to be interpreted as including devices for performing the methods and methods of using the devices. It should be understood that the features and / or steps described for one embodiment may sometimes be used with other embodiments, and not all embodiments of the invention have all the features and / or steps shown in the specific drawings or described for one particular embodiment. Tasks are not necessarily performed in the exact order described.
[0201] It should be noted that some of the above embodiments may include structures, behaviors, or details of structures and behaviors that may not be essential to the invention and are described as examples. As is known in the art, the structures and behaviors described herein may be replaced by equivalents that perform the same function, even if the structures or behaviors are different. The above embodiments are mentioned by way of example, and the invention is not limited to what has been specifically shown and described above. Rather, the scope of the invention includes both combinations and sub-combinations of the various features described above, as well as variations and modifications thereof not disclosed in the prior art that would arise to those skilled in the art upon reading the foregoing description. Therefore, the scope of the invention is defined only by the elements and limitations used in the claims, wherein the terms “comprise,” “include,” “have,” and their morphological variations, when used in the claims, should mean “including but not necessarily limited to.” Appendix A Instructions for Use, Pages 26 / 28, 29 CN 121623181 A
[0202] Effective diffusion distance measurement: 7-20 days after tumor inoculation, when the tumor transverse diameter is ~6-15 mm, a single DaRT seed (6.5 mm long, 0.7 mm outer diameter) carrying 2-3 uCi 224Ra is inserted into the center of the mouse tumor. Four to five days later, the tumor (as a whole) is removed and cut in half perpendicular to the seed axis at the estimated location in the seed center. Then the seed is removed using surgical forceps.The grains were extracted and placed in a water-filled tube for subsequent measurement with a gamma counter. The tumor was stored at -80°C for one hour. It was then removed in dry ice for measurement with the same gamma counter to determine its 212Pb activity. The measurements of grain and tumor activity were used to determine the probability of 212Pb leakage from the tumor.
[0203] Immediately after the gamma measurement, the two halves of the tumor were histologically sectioned using a cryostat. The sections were cut at 250–300 μm intervals and 10 μm thickness and placed on positively charged glass slides and fixed with 4% paraformaldehyde. Typically, there were 5–15 sections per tumor, spanning 1.5–5 mm in length. Shortly after their preparation, the glass slides were placed face down on a phosphorescent imaging plate (Fujifilm TR2040S) for one hour, which was protected by 12 μm Mylar foil and sealed in an opaque housing. Alpha particles emitted from the slice during the decay of 212Pb daughter atoms (212Bi and 212Po) penetrate the foil and deposit energy in the active layer of the phosphorescent imaging plate. The plate is then read out by a phosphorescent imaging scanner (Fujifilm FLA-9000).
[0204] For each tumor slice, the result is a two-dimensional intensity map proportional to the local 212Pb activity. The intensity (in units of photoexcited luminescence) is converted to 212Pb activity using a suitable calibrated sample measured simultaneously with the slide. The point where the seed passes through the slice is identified by the appearance of “holes” in the activity map or by taking the centroid of the activity distribution. Examples are shown in Figures 8A-8D. We define a region of interest (ROI) centered on the estimated seed location and divide it into concentric rings 0.1 mm wide with radii ranging from 0.5 to 3 mm. For each ring, we calculate the average activity. If the ROI extends beyond the area of the tumor slice, or includes areas with degraded tissue or reduced image quality, the average value of the rings is taken over a finite azimuthal sector. Then, based on a diffusion-leakage model, a curve of activity varying with radial distance from the origin (estimated seed location) is numerically fitted using a function describing the radial activity distribution from the seed. The seed is calculated as a line source perpendicular to the image. The source is divided into numerous point segments, each contributing activity to a given pixel in the image plane. In this expression, is the distance between the source segment and the pixel under consideration, and and are free parameters whose values are adjusted to optimize the fit to the entire curve (Figs. 8A–8D). The obtained values are taken as an estimate of the effective diffusion distance of the slice. The average value across all slices is taken to represent the effective (or primary) diffusion distance of the tumor, where the uncertainty is equal to the standard deviation of the values obtained across all slices.
[0205] Figure 8A shows the spatial distribution of photoexcited emission (PSL) signals in a histological section of a 4T1 tumor, where the sampled data area is indicated in white (0–4 mm) and the fitted area is indicated by a magenta dashed line (0.5–3 mm). Seed positions were determined manually.
[0206] Figure 8B is a radial activity distribution map of the sampled data from Figure 8A, fitted by a diffusion-leakage model.
[0207] Figure 8C shows the spatial distribution of PSL in another histological section from the same tumor, where seed positions were automatically determined by calculating the intensity centroid.
[0208] Figure 8D is a radial activity distribution map of the sampled data from Figure 8C, fitted by a diffusion-leakage model.
[0209] Figure 9 shows the measured effective diffusion distance as tumor mass changes for pancreatic tumors.
[0210] Figure 10 shows the measured effective diffusion distance as tumor mass changes for prostate tumors. Instruction manual, pages 27 / 28, 30 CN 121623181 A
[0211] Figure 11 shows the measured effective diffusion distance as tumor mass changes for melanoma tumors.
[0212] Figure 12 shows the measured effective diffusion distance as tumor mass changes for squamous cell carcinoma tumors.
[0213] Figure 13 shows the measured effective diffusion distance as tumor mass changes for triple-negative breast tumors.
[0214] Figure 14 shows the measured effective diffusion distance as tumor mass changes for GBM tumors. Appendix B
[0215] Rn Measurement Method: DaRT seeds are inserted into the tumor for a relatively short time (30 minutes), after which the seeds are removed (to prevent Pb buildup within the tumor). The tumor is then frozen and sliced into 10 µm thick sections perpendicular to the seed axis. These sections are placed on glass slides and fixed with formaldehyde. The tumor slices were then brought to a digital autoradiography system (iQID alpha camera, manufactured by QScint Imaging Solutions, LLC), which records alpha particle impacts one by one, providing their xy coordinates (accuracy ~20 μm), timestamps, and signals proportional to the deposition energy.
[0216] An example of images consisting of four histological slices of a DaRT-treated tumor and acquired using the iQID system is shown in Figure 15. Figure 15 shows four histological slices of a DaRT-treated tumor acquired using the iQID autoradiography system. For analysis, the images were cropped so that each slice was analyzed independently, as can be observed in Figure 16A, which shows a single histological slice used for analysis. For each slice, a center was selected (by the centroid method or by identifying “holes” in the activity map), and the average alpha particle count was calculated at radial distances increasing from the center. Then, the alpha particle count was analyzed by means of a false...Suppose the recorded activity map is a superposition of infinitely small segments along the DaRT grains, and the resulting map is numerically fitted, where each segment is calculated using Equation 1:
[0217] In this expression, is the radial distance between the grain segment and the point of interest on the image, is the radon diffusion distance, and is a free parameter. These two parameters are found using a least-squares fitting method.
[0218] The fitting is performed over a finite activity distribution area to avoid artificial “holes” at the center of the distribution (where the DaRT grains are located) and at the far ends, where statistical variation is excessive. An example of the fitted curve is shown in Figure 16B, which shows the calculated average count as a function of distance from the grain location, including the fitted function. Instruction manual page 28 / 28, page 31, CN 121623181 A, Figure 1; Instruction manual figure 1 / 24, page 32, CN 121623181 A, Figure 2; Instruction manual figure 2 / 24, page 33, CN 121623181 A, Figure 3; Figure 4; Instruction manual figure 3 / 24, page 34, CN 121623181 A, Figure 5; Figure 6A; Instruction manual figure 4 / 24, page 35, CN 121623181 A, Figure 6B; Instruction manual figure 5 / 24, page 36, CN 121623181 A, Figure 6C; Instruction manual figure 6 / 24, page 37, CN 121623181 A, Figure 6D; Instruction manual figure 7 / 24, page 38, CN 121623181 A, Figure 6E; Instruction manual figure 8 / 24, page 39, CN 121623181 A, Figure 6F; Instruction manual figure 9 / 24, page 40, CN Figure 7A, Appendix to the Instruction Manual, Page 10 / 24, CN 121623181 A; Figure 7B, Appendix to the Instruction Manual, Page 11 / 24, CN 121623181 A; Figure 7C, Appendix to the Instruction Manual, Page 12 / 24, CN 121623181 A; Figure 7D, Appendix to the Instruction Manual, Page 13 / 24, CN 121623181 A; Figure 7E, Appendix to the Instruction Manual, Page 14 / 24, CN 121623181 A; Figure 7F, Appendix to the Instruction Manual, Page 15 / 24, CN 121623181 A; Figure 7G, Appendix to the Instruction Manual, Page 16 / 24, CN 121623181 A; Figure 8A, Appendix to the Instruction Manual, Page 17 / 24, CN 121623181 A; Figure 8B, Appendix to the Instruction Manual, Page 18 ... CN 121623181 A; Figure 8B, Appendix to the Instruction Manual, Page 18 / 24, CN 121623181 A; Figure 8C, Appendix to the Instruction Manual, CN 121623181 A; Figure 8D, Appendix to the Instruction Manual, Page 17 / 24, CN 121623181 A; Figure 8B, Appendix to the Instruction Manual, CN 121623181 A; Figure 8C, Appendix to the Instruction Manual, Page 18 / 24, CN 12121623181 A Figure 8C Instruction Manual Appendix 19 / 24 Page 50 CN 121623181 A Figure 8D Figure 9 Instruction Manual Appendix 20 / 24 Page 51 CN 121623181 A Figure 10 Figure 11 Instruction Manual Appendix 21 / 24 Page 52 CN 121623181 A Figure 12 Figure 13 Instruction Manual Appendix 22 / 24 Page 53 CN 121623181 A Figure 14 Figure 15 Instruction Manual Appendix 23 / 24 Page 54 CN 121623181 A Figure 16A Figure 16B Instruction Manual Appendix 24 / 24 Page 55 CN 121623181 A ABSTRACT This application relates to activity levels for diffusing alpha-emitter radiation therapy. Disclosed herein is a method for treating a cancerous tumor, by implanting in the cancerous tumor at least one diffusing alpha-emitter radiation therapy (DaRT) source with a suitable radon release rate and for a given duration, such that the source provides during the given duration a cumulated activity of released radon of at least 10 Mega becquerel (MBq) hour, per centimeter length. Optionally, the sources are implanted in an array of sources, each source separated from its neighboring sources in the array by not more than 4.5 millimeters.
Claims
1. A kit for implanting diffusing alpha-emitter radiotherapy sources into a cancerous tumor, wherein the kit comprises diffusing alpha-emitter radiotherapy sources with radium-224 mounted on a support, wherein the diffusing alpha-emitter radiotherapy sources are implanted in an array in which each diffusing alpha-emitter radiotherapy source is spaced no more than 3.9 millimeters from its neighboring diffusing alpha-emitter radiotherapy sources.
2. The kit of claim 1, wherein the diffusing alpha-emitter radiotherapy sources are implanted in a hexagonal arrangement.
3. The kit of claim 1, wherein each diffusing alpha-emitter radiotherapy source in the array is spaced between 3.1 millimeters and 3.9 millimeters from its neighboring diffusing alpha-emitter radiotherapy sources.
4. The kit of claim 1, wherein each diffusing alpha-emitter radiotherapy source in the array is spaced no more than 3.7 millimeters from its neighboring diffusing alpha-emitter radiotherapy sources.
5. The kit of claim 1, wherein each diffusing alpha-emitter radiotherapy source in the array is spaced no more than 3.5 millimeters from its neighboring diffusing alpha-emitter radiotherapy sources.
6. The kit of any one of claims 1-5, wherein each diffusing alpha-emitter radiotherapy source in the array is spaced at least 3.3 millimeters from its neighboring diffusing alpha-emitter radiotherapy sources.
7. The kit of any one of claims 1-5, wherein the cancerous tumor is a melanoma tumor.
8. The kit of any one of claims 1-5, wherein the cancerous tumor is a prostate cancer tumor.
9. The kit of any one of claims 1-5, wherein the cancerous tumor is a pancreatic cancer tumor.
10. The kit of any one of claims 1-5, wherein the cancerous tumor is a glioblastoma tumor.
11. An apparatus for preparing a radiotherapy treatment, comprising: an input interface to receive information about a tumor; a processor configured to identify the tumor as a cancerous tumor and generate a placement of diffusing alpha-emitter radiotherapy sources for the tumor, wherein the diffusing alpha-emitter radiotherapy sources in the placement are arranged in a regular pattern with a distance of no more than 3.9 millimeters between adjacent diffusing alpha-emitter radiotherapy sources; and an output interface to display the placement to a human operator.
12. The apparatus of claim 11, wherein the distance between adjacent diffusing alpha-emitter radiotherapy sources is no more than 3.7 millimeters.
13. The apparatus of claim 11, wherein the diffusing alpha-emitter radiotherapy sources in the placement are arranged in a hexagonal arrangement.
14. The apparatus of claim 11, wherein the distance between adjacent diffusing alpha-emitter radiotherapy sources is between 3.1 millimeters and 3.9 millimeters.
15. The apparatus of claim 11, wherein the distance between adjacent diffusing alpha-emitter radiotherapy sources is no more than 3.5 millimeters.
16. A method of preparing a radiotherapy treatment, comprising: receiving a request for a diffuse alpha-emitter radiotherapy source for a cancerous tumor; determining a number of diffuse alpha-emitter radiotherapy sources required for the cancerous tumor such that a tumor region is covered by the diffuse alpha-emitter radiotherapy sources with a spacing between the diffuse alpha-emitter radiotherapy sources of no more than 3.9 millimeters; and providing a kit comprising the determined number of diffuse alpha-emitter radiotherapy sources.
17. The method of claim 16, wherein determining a number of diffuse alpha-emitter radiotherapy sources required for the cancerous tumor comprises determining the number such that a tumor region is covered by the diffuse alpha-emitter radiotherapy sources with a spacing between the diffuse alpha-emitter radiotherapy sources of no more than 3.5 millimeters.
